Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Jie Zhang1,*, Jinghua Jiao2,*, Meng Niu3,*, Xiaotong Gao4, Guisen Zhang5, Honghua Yu6,*, Xiaohong Yang5

1Department of Ophthalmology, Weifang Eye Hospital, Weifang, 261041, People’s Republic of China; 2Department of Anesthesiology, Central Hospital, Shenyang Medical College, Shenyang, 110024, People’s Republic of China; 3Department of Radiology, First Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 4Department of Endocrinology and Metabolism and the Institute of Endocrinology, The First Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 5Department of Ophthalmology and Annan Medical University, Shenyang, 110001, People’s Republic of China; 6Department of Ophthalmology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences; School of Medicine, South China University of Technology, Guangzhou, 510120, People’s Republic of China; 7Department of Ophthalmology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, People’s Republic of China

*These authors contributed equally to this work

Abstract: The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier-based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier-based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

Keywords: nano-carrier, nanomedicine, ocular disease, drug delivery system

Key Summary Points
- This review offers a comprehensive overview of nano-medicine-based treatments for ocular disorders in the last decade.
- Nanotechnology-based drug delivery systems will probably be used by ophthalmologists in the near future, allowing benefits such as reduced side effects, and less frequent dosing, among others.
- Active targeting ligands related to nano-medicine in ocular therapeutics have yet to be addressed to test their effects and safety.
- Further nanomedicine clinical trials for ocular disorders are needed until this promising pharmacological innovation becomes available in the ophthalmologist’s daily therapeutic practice.

Introduction
The eye is one of the most sensitive organs and consists of several barriers and defense mechanisms to protect it from the environment. For example, it is challenging to deliver drugs to different compartments of the eye and treat ocular disorders due to this specific anatomy, such as the blood-aqueous barrier (BAB) and blood
retinal barrier (BRB). Additionally, the bioavailability of drugs after ocular administration may be less than 5%, which is often insufficient. At present, commonly used drug dosage forms to treat eye diseases include eye drops, eye ointments, and eye gels. Due to the numerous ocular barriers, including the tear film barrier, the corneal barrier, the conjunctival barrier, the scleral barrier, as well as the BAB and BRB, challenges, such as delivery of drugs to less accessible parts of the eye, are often encountered. Therefore, innovating ocular particulate drug delivery systems (DDSs) with sustained release effects or increasing permeability have become a recent research hotspot. These particulate DDSs mainly include liposomes, emulsions, micelles, dendrimers, and microspheres. The conventional administration route for an ocular DDS mainly includes the ocular surface and the intraocular (such as intravitreal and suprachoroidal space) and periorbital tissues. Due to the different barrier effects of each part of the eye, the factors affecting the administration of each route are not the same. The design of a novel ocular DDS has become a central issue to achieve efficient delivery of drugs to different parts of the eye. In the past, nanomedicine was mainly concentrated in the treatment of ocular surface diseases and glaucoma. However, in the last 10 years, nanomedicine has rapidly developed in ophthalmology to include fundus lesions and ocular tumors. Loading the drug into an ocular nano-level DDS enhances its solubility, stability, and permeability, while extending residence time, thereby enhancing drug efficacy.

To provide an overview of recent advancements in ocular nanomedicine, we herein review the current evidence of various nano-micro matrices based on several conventional materials (eg, liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions) for ophthalmological applications reported over the last decade (2011–2020). Notably, recent advances in nanocarrier DDSs as well as their effects in the treatment of various ophthalmic diseases are comprehensively introduced. Finally, current challenges and future directions and perspectives about nanocarrier-based DDS applications for ocular therapeutics are further discussed.

**Structure of the Eyeball for Drug Delivery**

The diameter of the adult eyeball is about 24 mm, which is composed of the ocular wall and the contents of the eyeball. The anterior segment of the eyeball mainly consists of the cornea, conjunctiva, iris, ciliary body, sclera, aqueous humor, and the lens, while the posterior segment mainly includes the vitreous body, retina, choroid, and sclera. The eyeball has a unique anatomical structure called the blood-eye barrier, which makes it difficult to achieve an effective drug concentration. Due to the lipophilic surface layer of the cornea and the hydrophilic nature of the inner layer, ointments do not have characteristics of being both fat-soluble and water-soluble, which makes it difficult to achieve an effective intraocular concentration after applying topical medications. The effective intraocular drug concentration is the key to the treatment of many ocular disorders. Therefore, changing the administration route and dosage form of ophthalmic drugs is an important measure to increase the intraocular drug concentration.

**Traditional Delivery of Ocular Drugs**

The traditional administration methods for treating eye diseases include local administration or systemic administration (Figure 1). Local administration includes periocular (subconjunctival, subtenon, posterior juxtascleral, retrolubular, and peribulbar) and intravitreal injections. However, these drug delivery routes are limited. Local administration on the ocular surface (cornea, conjunctiva, sclera, and anterior uvea) is usually adopted in the clinic to treat ocular diseases. Generally, eye drops are quickly discharged from the surface of the eye. In addition, due to technological advancements and drug development, such as antiangiogenic drug (bevacizumab, ranibizumab, aflibercept, and conbercept) therapy and glucocorticoids, intravitreal injections are used for retinal and vitreous diseases. This local administration route also has many challenges, such as poor patient compliance and potential adverse effects (eg, endophthalmitis, cataracts, or retinal detachment). Only 1% to 2% of systemically administered drugs reach the target tissue due to the effects of the BAB and the BRB. In addition, large doses and frequent systemic administration can cause adverse effects. Recent studies have shown that nano-carriers are useful to deliver hydrophilic or lipophilic drugs to the eye, prolonging the half-life of drugs in the vitreous, and improve the bioavailability of many drugs, including proteins and peptides. Interestingly, applications of polymeric nano-micelles have been tested for intraocular and surface ocular disease treatment. Furthermore, nanotechnology protects the drug from degradation both in the in vivo circulation and under storage conditions. Consequently, a new ophthalmic DDS with sustained release, strong penetration, and long duration in the eye is needed.
Ocular Nano-Drug Delivery System

Advantages of Nano-Drugs and DDS

A DDS with nanoscale spatial resolution plays a key role in making ocular tissue an attractive pharmacological target for therapies against disorders. Three different advantages of utilizing DDS include: (1) Promoting absorption: promote the passage of the drug through tissues acting as a barrier; (2) Controlled release: local administration effectively controls timed- and sustained release; (3) Targeted drugs: use drugs that are effective and act specifically on the target tissues.\(^{22,23}\) The development of DDS nanotechnology has made it possible to overcome eye-related obstacles.

Many promising vehicles are available for ocular DDS, such as nanoemulsions, liposomes, nanomicelles, nanosuspensions, and polymeric and lipid nanoparticles.\(^{24}\) Nanocarriers for eye DDSs have the following advantages: (1) A nano-material carrier can enter the capillaries through the blood circulation, and penetrate the endothelial cell gap, enter the lesion, and be absorbed by pinocytosis to improve bioavailability of the material. (2) Nano-carrier particles are small with a high specific surface area, which can embed hydrophobic substances, improve solubility, and reduce the side effects of conventional solvents. (3) A nano-material carrier can be modified by the targeting group to realize targeted drug delivery, which can reduce the dosage and side effects, such as folic acid-modified nanoparticles and magnetic nanoparticles.\(^{25}\) (4) Nanocarriers prolong the elimination half-life (t1/2beta) of a substance, increase effective blood concentration time, increase efficiency, reduce frequency of use, and reduce toxic and side effects. (5) Nanocarriers pass through the barriers of the body that limit the effects of substances, such as the blood-brain barrier, the blood-eye barrier (BAB and BRB) and the cell biomembrane barrier, so substances reach the lesion. (6) Nanocarriers improve the interactions between drugs and the cornea and conjunctival epithelium, which improve the efficiency of delivery and bioavailability of drugs.\(^{24,26–28}\)
Common Nano-Carriers for Ocular Drug Delivery

The nano-carrier DDS has become a hotspot in the field of ophthalmic preparation research. Ophthalmic nano-carrier DDSs mainly include liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions. Based on the special molecular structure and biological characteristics, the ophthalmic preparations of DDSs have advantages of sustained and controlled drug release as well as targeting and are advantageous for carrying ophthalmic sustained release systems.

Liposomes

A liposome is a double-layered membrane structure formed spontaneously during the water phase by phospholipid molecules under hydrophobic forces.\(^{29,30}\) The amphiphilic characteristics make it possible to load fat-soluble drugs between the double-layered membranes and to wrap water-soluble drugs in the center. Liposomes are highly biocompatible and degradable, reduce drug toxicity, and realize sustained drug release. In addition, liposomes interact with cells, including adsorption on the cell surface, fusion with cell membranes, exchange of phospholipid components with cell membranes, and endocytosis.\(^{30-33}\) Based on these characteristics, the potential of liposomes as drug delivery vehicles has been under development for the past 10 years.

Liposome is an ideal DDS in the field of ophthalmology because their structure is like a cell membrane that encapsulates hydrophilic and hydrophobic drugs. The efficiency of liposomes in the eye is related to their biocompatibility, size, charge, stability, residence time, the encapsulation rate, and distribution of the drug.\(^{22,34,35}\)

In 1981, Smolin et al first reported the use of liposomes as ophthalmic drug carriers. They demonstrated that liposomes coated with iodides are more effective than ordinary eye drops for treating rabbit herpes simplex virus keratitis.\(^{36}\) In 1988, Simmons et al injected 5 mg of 5-fluouracil (5-FU) liposomes under the conjunctiva of rabbits to prevent scarring of the filtering mouth fibers after filtration in cases of glaucoma. It is believed that this improves the success rate of surgery and more secure.\(^{35}\) Studies have revealed that the clearance rates of liposomes in eyes with aphakia and those that underwent vitrectomy are faster, which is believed to be related to the increase in intraocular convection and molecular movement after vitrectomy. Experiments have also confirmed that the clearance rate of liposomes is inversely proportional to the size of the liposome.\(^{37}\) Larger liposomes have been speculated to be more stable Barza et al designed a set of experiments to study the effect of liposome size and lipid composition on pharmacokinetics.\(^{38}\) Arroyo et al reported that a conventional liposome formulation has the same effects on reducing intraocular pressure (IOP) compared to eye drops, and the effective time was significantly longer using a concentration 10-fold lower.\(^{39}\) In addition, local delivery of liposomes improves the bioavailability of drugs to posterior eye tissues (such as the retina).\(^{40}\)

Zhang et al investigated the efficacy of an intravitreal injection of liposomes encapsulating infliximab in rats with experimental autoimmune uveoretinitis (EAU) and reported that liposomes prolong the persistence of the drug in the vitreous body and demonstrated a satisfactory safety and significant therapeutic potential in EAU.\(^{41}\) Additionally, Tan et al showed that the permeability and bioavailability of chitosan-modified liposomes were 2 and 3.9 times higher than those of unmodified liposomes containing a timolol maleate solution alone (1.71 times). Moreover, chitosan-modified liposomes continuously release drug in the eye tissues for 4 hours and unmodified liposomes release drug for 2 hours, which has a better effect on reducing IOP.\(^{42}\) The use of biodegradable particles for therapeutic antibody delivery provides a promising approach for treating ocular diseases.

Nanoparticles

Nanoparticles are formed by self-assembly of natural degradable phospholipids in the water phase and have bi-continuous micro-structural characteristics.\(^{43}\) Cubic liquid crystal nanoparticles have advantages for lipid soluble and amphiphilic drug loading compared with liposomes due to the size of the bilayer region. Therefore, good biodhesion is another outstanding advantage of cubic liquid crystal nanoparticles.\(^{44}\) Furthermore, the common phospholipid used in calcium carbonate liquid crystal nanoparticles is glycerol monooleate.

Nanoparticles have attracted the most attention as a delivery system to locally treat ocular diseases. The distribution of nanoparticles in the eye mainly depends on their size and surface properties. Nanoparticles of 200 to 2000 nm remain in the eye tissue for at least 2 months.\(^{45}\) Nanoparticles adhere to the mucosa and remain in the anterior corneal tissue for a long time without rapid removal. Drugs can be encapsulated, conjugated, or adsorbed in nanoparticles. Biodegradable polymers, such as alginate, chitosan, gelatin, polycaprolactone, polyactic acid or poly lactic co-glycolic acid (PLGA), are the most widely used polymers for preparing nanoparticles.\(^{46,47}\) Varshochianand et al\(^{48}\) used albumin PLGA nanoparticles...
containing bevacizumab to treat ocular angiogenesis. The nanoparticles were prepared using the double emulsion method and injected into the rabbit vitreous body in a single dose. The results showed that the concentration of bevacizumab was more than 500 g/L and was extended for about 8 weeks. Mahaling et al.\(^4\) prepared a core-shell nanoparticle system to deliver triamcinolone acetonide non-invasively to the retina using a slowly degrading polycaprolactone core. They reported that the drug-loaded nanoparticles significantly improved both structural and functional activities of the retina. Furthermore, expression of retinal inflammatory biomarkers, such as nuclear factor-kB, intercellular adhesion molecule-1 (ICAM-1), and tumor necrosis factor-α (TNF-α) were reduced by the intervention. Wang et al.\(^5\) developed biodegradable nanoparticles loaded with dexamethasone sodium phosphate (DSP) using zinc ion bridging (DSP-Zn-NP) with dense coatings of poly (ethylene glycol) (PEG). As results, the nanoparticles were safe after subconjunctival administration in rats and provided continuous DSP administration. A single subconjunctival administration inhibited corneal angiogenesis in rats within 2 weeks. These results suggest that subconjunctival administration of DSP-Zn-NP could be an effective strategy for preventing and treating corneal neovascularization (CNV).

**Nanosuspensions**

Unlike traditional matrix-framework nanosystems, nanosuspensions do not require carrier materials. A nanosuspension is a versatile formulation combining conventional and innovative features. It comprises 100% pure drug nanoparticles with sizes in the nano-scale range, generally stabilized by surfactants or polymers. After the drug is prepared in a nanosuspension, reducing the particle size increases the contact area and residence time of the drug with the cornea, and increasing the concentration of the drug in the infected tissue and the solubility of a poorly soluble drug improve bioavailability.\(^45\) Luschmann et al. prepared a cyclosporine (CsA) nanosuspension and micellar formulations and evaluated their tolerance and drug release in corneal tissue using the rabbit eye model.\(^51\) The results showed that the drug concentrations in the corneal tissues of the rabbits in the nanosuspension and micelle groups were much higher than that in the commercially available Restasis\(^6\) group. After topical administration of a hydrocortisone nanosuspension prepared by Ali et al., the hydrocortisone nanosuspension had a larger area under the curve (AUC) and a retention time of 9-hours in the local eye tissue, while the drug solution alone only maintained a 5-hour retention time.\(^52\) Similarly, other studies have suggested that nanosuspensions successfully deliver other drugs, such as pranoprofen,\(^53\) triamcinolone acetonide,\(^54\) and moxifloxacin,\(^55\) to eye tissues.

**Nanomicelles**

Nanomicelles are nanostructures formed spontaneously in an aqueous environment by block copolymers with amphiphilic properties.\(^56\) The lipophilic portion is composed of the micelle core that encapsulates the hydrophobic drug, while the hydrophilic part is composed of the outer surface of the micelle to increase drug solubility.

Nanomicelle carriers formed by self-assembly of block polymers containing hydrophilic and hydrophobic segments have attracted increasing attention as non-invasive ophthalmic DDSs. The amphiphilic nature of nanomicelles makes it easy for them to penetrate lipophilic corneal epithelial and endothelial cells, and they can also penetrate a hydrophilic matrix, which overcomes the solubility problems of poorly soluble drugs, promotes drug penetration, and improves bioavailability. In addition, nanomicelles are small in size and are easily taken up by corneal cells.\(^57\) Polymeric micelles have been demonstrated to improve the bioavailability of drugs in anterior eye tissues, help spread the drug in the sclera, and produce a sustained drug delivery effect of ophthalmic applications.\(^58\) Wu et al. reported that an intravitreal injection of labeled methoxy polyethylene glycol-block-polycaprolactone (mPEG-PCL) micelles loaded with rapamycin exists in retinal pigment epithelial cells for at least 14 days, which significantly prolongs the retention time of the drug in the retina.\(^59\) The micelle system had a better therapeutic effect on autoimmune uveitis in rats compared with the rapamycin suspension system alone. Cholkar et al. prepared cyclosporine-loaded nanomicelles and studied the tissue distribution of CsA in rabbit eyes.\(^60\) The CsA concentration in the anterior eye tissue was highest after local instillation, but a higher level of CsA (53.7 ng/g) was detected in the retina, suggesting that nano-micelles have the potential to deliver drugs to eye tissues.

**Microemulsions/Nanoemulsions**

Other nanotechnology-based carriers, particularly nanomicelles (NEs) and microemulsions (MEs) have various applications in drug delivery research.\(^61\) Furthermore, they are potential drug solubilizers that enhance penetration through their high surfactant/co-surfactant contents.\(^62\) NEs are highly stable, with low toxicity and irritation,
large drug loading capacity, and greatly improved drug bioavailability. NEs are some of the most researched and applied nano-carriers DDSs in the field of ocular local drug delivery. After local administration to the eye, NEs are mainly absorbed through the cornea.63,64 Furthermore, the emulsion is composed of an oil phase, a water phase, an emulsifier, and a co-emulsion. The emulsion prolongs contact time between the drug and corneal epithelial cells, promotes absorption of the drug by the cornea, sclera or conjunctiva, and improves adhesion of the emulsion.65 Although NEs have many physical, chemical, and physiological advantages, their absorption and distribution are affected by the structure of the corneal layers.

Kalam et al confirmed that optimized MEs possess good stability, show greater adherence to the corneal surface, and diffuse gatifloxacin into the anterior chamber of the eye, resulting in a two-fold increase in gatifloxacin concentration than the conventional dosage form.66 Subsequently, Kesavan et al67 evaluated the mucoadhesive chitosan-coated cationic microemulsions (CH-MEs) to deliver dexamethasone to treat uveitis in vitro and in vivo. The inhibitory rate of CH-MEs on inflammatory cells was 93.4%, and the protein content was reduced to 6.46 g/l, which was better than dexamethasone alone (the inhibitory rate of inflammatory cells was 62.14%, and the protein content was reduced to 16.15 g/l), indicating that a chitosan-coated dexamethasone emulsion has good mucosal adhesion and release characteristics. In addition, this emulsion interacts with the lipid layer of the tear film, and is retained in the conjunctival sac for a longer time, where it acts as a drug reservoir.

**In situ Gelling Drug Delivery Systems and Others**

In situ gelling drug delivery systems have gained enormous attention in the area of ophthalmology over the last decade. In situ gelling drug delivery systems are in a sol-state before administration, and capable of forming gels in response to different endogenous stimuli.68 Such systems can be administered through different routes, to achieve ocular drug delivery and can also be successfully used as vehicles for drug-loaded nano- and micro-particles to treat ocular diseases.69 Other nano-preparations, such as liposomes and nanoparticles have been combined to prepare composite systems to further extend the retention time of drugs on the ocular surface and improve their bioavailability.70 Quality control of the nanocomposite gel system is comprehensive. It is necessary to consider the quality of the entire system, including stability of the gel and the gelling performance of the in-situ gel at the macro level. Notably, the nano-gel composite system uses many auxiliary materials, and safety should be the focus. The eye irritation test for dorzolamide ME gel composite formulations shows that the it is non-irritating utilizing the Draize technique, but that study did not compare MEs and the gel matrix.71 It is recommended to set up a comparison between a single formulation and the corresponding matrix for a safety evaluation of a composite system, which provides a reference for designing new composite formulations.

Göttel et al developed a new solid in-situ gelling system for topical ocular therapeutics (Figure 2).72 Electrospraying an amylopectin-gellan gum solution produces nanofibers with high porosity and a narrow size distribution. Nano-computed tomography (CT) imaging produces a non-invasive and detailed 3D visualization of the internal structure of nanofibers.73 Rheological experiments showed that gelation behavior continued to occur after spinning. Researchers improved the application of fiber optic lenses in the eye using a 3D printed matrix to produce bending. This system can be easily processed and applied. A new 3D printing model has been developed to determine the residence time in vitro pig eyes.74 As results, rapid dissolution and uniform distribution were observed on the porcine cornea with extended eye residence time. In the future, this new solid in-situ gelation system might be an attractive alternative to existing ophthalmic DDSs.

**Nano-Drug Preparations and Therapeutic Effects for Different Eye Diseases**

Many studies have focused on evaluating the preliminary therapeutic effects of drug loaded nanoformulations in ocular therapeutics in vitro and in vivo. Few drug loaded nanoformulations have been used in clinical research, possibly because it remains challenging to reach the internal structure of the eye through local infusion, and there are still some problems in nano preparation, such as poor stability, difficulties with sterilization, low drug loading, and high costs. Due to the strong irritation of excipients and incomplete drug release, the research progress on nano-level eye drops is still relatively slow. In the following sections, we describe the application of nano drug delivery systems in different types of ocular disorders.

**Conjunctivitis**

The most common ocular surface disease is conjunctivitis, which is a common cause of eye redness and is common in
emergency rooms, as well as emergency care and primary clinics. It can affect people of any age and demographic or socioeconomic status. According to pathogenic examination, the disease is divided into bacterial, viral, fungal, parasitic, allergic, and chlamydial conjunctivitis.

The main symptoms of conjunctivitis include red itchy eyes, palpebral edema, excessive tearing, along with a yellowish mucous discharge. It is usually self-limiting and rarely causes loss of vision, but it often requires treatment to relieve symptoms and shorten the disease course. The treatment recommendations for conjunctivitis include pharmacological therapy targeting causes, such as antibiotics, antivirals and antifungals and anti-allergy medications. The common route of administration for ocular diseases is local administration on the ocular surface, of which, eye drops, ointments, and gels are the main dosage forms. However, because the conjunctival sac holds less fluid and affects eye blink behavior as well as orbicularis oculi muscle activity, the drug only stays on the ocular surface for a short time, which ultimately leads to a short time of the effective therapeutic concentration on the ocular surface. Interestingly, nanotechnology opens a new avenue for treating ocular diseases, particularly ocular surface disorders. Nano-carrier DDSs have the potential to reduce drug degradation, increase permeability and bioavailability, and prolong retention time by tailoring the release profile, thereby achieving sustained drug release and targeted therapeutic concentrations, which have been shown in in-vitro or animal studies.

The main advantage of adding anti-infective/anti-inflammatory drugs to a nano-carrier is to extend the residence time of the drug and improve bioavailability of the drug in the eye. Many studies have been performed on anti-allergy drugs loaded with nano-carrier DDSs for allergic conjunctivitis treatments (Table 1). Allergic conjunctivitis has immune-pathophysiology, in which, topical non-steroidal anti-inflammatory drugs (NSAIDs) and immune modulators are conventional treatment. For example, the NSAID flurbiprofen has low penetration across the cornea...
and produces ocular irritation. Deformable chitosan-coated flurbiprofen-loaded liposomes were proposed and these flexible liposomes easily move across the pores which are too small for conventional liposomes to pass, as their bilayers are highly curved. Another NSAID, dexibuprofen, loaded onto biodegradable polymeric PLGA nanoparticles constitutes a suitable alternative to topical eye administration. These nanoparticles improve ocular bioavailability and simultaneously reduce drug-induced side effects. Tacrolimus is a common immune modulator that has been loaded onto PLGA nanoparticle and proglycosomes to provide continuous sustained drug release without side effects (Figure 3).

### Keratitis

Keratitis is characterized by corneal edema, infiltration of inflammatory cells, and ciliary congestion and has symptoms, such as eye red, decreased vision, photophobia, difficulty opening the eyelids upon awakening, and excessive tearing. Keratitis is classified as infectious or non-infectious based on the etiological agent. The infectious type is subdivided into bacterial, protozoal (Acanthamoeba), pythium, fungal, viral, and onchocercal keratitis. Topical chloramphenicol is one of most commonly used drugs against all bacterial isolates, but it has some disadvantages, such as low solubility and short residence time in the conjunctival sac.

### Table 1 Nanocarriers to Deliver Anti-Conjunctivitis Agents

| Study                          | Drug      | Vehicle/Carriers | Production Method(s)          | Results                                                                 | Conclusion                                                                 |
|--------------------------------|-----------|------------------|------------------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| E. Sanchez-Lopez, et al 2020   | Dexibuprofen | PLGA nanoparticles | Solvent displacement method | Polyethylene glycol (PEG) increased the interaction between Dexibuprofen-NPs and customized corneal membrane. | These formulations containing DXI PLGA 15% PEG prepared using Lutrol as a surfactant were able to release DXI more effectively for the treatment of ocular inflammation. |
| X. Gai, et al 2018             | Ibuprofen | Liposomal         | Ethanol injection method     | Ibuprofen cationic liposomes could significantly prolong the T max to 100 min and the AUC to 1.53-folds, which indicated that the ibuprofen cationic liposomes could improve the precorneal retention time and bioavailability of ibuprofen. | The ibuprofen cationic liposomes probably are a promising application in ocular drug delivery system. |
| Y. Xu, et al 2017              | Tacrolimus | PLGA nanoparticles | Emulsification-diffusion method | PLGA-NPs improved corneal, conjunctival and aqueous humor bioavailability of Tacrolimus. | The PLGA-NPs significantly enhanced ocular bioavailability of TAC than that of aqueous suspension. |
| V. Garg, et al 2017            | Tacrolimus | Proglycosomes     | Film hydration method        | Incorporation of proglycosomes enhanced the drug encapsulation, decreased the vesicle aggregation and increased the liposomal elasticity, thereby enhancing the transocular permeation. | The developed proglycosomes are prospective carriers for enhanced ocular delivery of tacrolimus. |
| H. Chen, et al 2016            | Flurbiprofen | Chitosan-coated liposomal | Modified ethanol injection method | Flurbiprofen-loaded deformable liposomes could prolong pre-corneal retention and improve transcorneal penetration. Edge activator, Solutol HS-15, could potentiate its flexibility and penetrability. | Chitosan-coated deformable liposomes appear to be a novel ophthalmic drug delivery system with the potential to overcome the limitations of conventional eye drops. |

**Abbreviation:** ⁎PLGA, poly (lactic-co-glycolic acid).
In order to solve these problems, Xu et al prepared chloramphenicol-containing cyclodextrin eye drops containing chloramphenicol to treat acute bacterial keratitis. Furthermore, the drug concentration in the aqueous humor using CHL/SBE-β-CD eye drops was higher than that of commercial chloramphenicol eye drops, and the average ocular surface stay time was 1.9 times longer. Zorzi et al developed PEGylated polymeric vesicles encapsulating small interfering RNA (siRNA) sequences to treat keratitis caused by Acanthamoeba. The combined therapy of siRNA-loaded polymeric vesicles with chlorhexidine led to a 60% reduction in corneal damage caused by Acanthamoeba in a 2 month-old Wistar rat model. Further studies should be performed to confirm the effectiveness of this treatment.

Dry Eye Disease

Dry eye disease (DED) is one of the most common ocular surface disorders characterized by a deficiency of tear production or excessive tear evaporation. The common symptoms of DED include a dry, foreign body sensation, burning, itching, photophobia, congestion, pain, blurred vision, fatigue, and a sticky silk secretion. Treatments for DED aim to improve these clinical symptoms using artificial tears and lubricants to moisten the ocular surface. In the last decade, nano-carrier systems have shown great promise to revolutionize drug delivery to treat DED, offering many advantages such as site-specific and sustained delivery of therapeutic agents. A number of studies have shown that nanotechnology drugs have a good therapeutic effect on the dry eye rabbit model (Table 2). For example, cyclosporine A, a poorly soluble immunosuppressant cyclic peptide required in some cases of xerophthalmia (severe drying and thickening of the conjunctiva), has been the subject of previous studies involving micelles. Kang et al used polyoxyl 35 hydrogenated castor oil micelles to demonstrate improved functionality and morphology of the conjunctival epithelium in a New Zealand albino rabbit dry eye model. In 2019, the NSAID amfenac loaded with poly(catechin) capped-gold nanoparticles had a synergistic anti-inflammatory effect in a DED rabbit model. Nagai et al loaded nanoparticles with rebamipide using the breakdown method and reported that this drug increases the mucin levels in the lacrimal fluid and prolongs tear film breakup time. These results will be

Figure 3 Tacrolimus is a common immune modulator that has been loaded onto Poly(lactic-co-glycolic acid) nanoparticle. Hypothetical representation of the location of propylene glycol in the vesicles and its effects as a novel drug delivery system for tacrolimus. Reprinted from Colloids Surf B Biointerfaces, 157, Garg V, Suri R, Jain GK, Kohli K. Proglycosomes: a novel nano-vesicle for ocular delivery of tacrolimus, 40–47, Copyright 2017, with permission from Elsevier.

Abbreviation: PNVs, Proglycosomes nano-vesicles.
| Study | Experimental Models | Drug | Vehicle/Carriers | Production Method(s) | Results | Conclusion |
|-------|---------------------|------|------------------|----------------------|---------|------------|
| N. Nagai, et al\(^{93}\) 2020 | N-acetylcysteine-treated rabbit model | Rebamipide | Nanoparticles | Breakdown method | The rebamipide solid nanoparticle-based ophthalmic formulation increased mucin levels in the lacrimal fluid and healed tear film breakup levels in vivo. | This novel sustained-release drug delivery route and creation of a nano-formulation can be used to design further studies aimed at therapy for dry eye. |
| F. Yu, et al\(^{161}\) 2019 | Dry eye murine model | Glycol chitosan cerium oxide | Nanoparticles | Unspecified | Glycol chitosan cerium oxide nanoparticles not only ameliorate symptoms but also reverse pathological changes at the cellular and molecular levels in dry eye. | Glycol chitosan cerium oxide nanoparticles are an effective treatment for dry eye and may represent a potential new class of drug for dry eye disease. |
| Y. J. Li, et al\(^{82}\) 2019 | Rabbits model | Amfenac | Poly(catechin) capped-gold nanoparticles | Unspecified | Poly (catechin) capped-gold nanoparticles (Au@Poly-CH NPs) not only act as an anti-oxidant to suppress ROS-mediated processes, but also serve as a drug carrier of AF for a synergistic effect on anti-inflammation. | Au@Poly-CH NPs loaded with NSAIDs is a promising multifunctional nanocomposite for treating various inflammation- and oxidative stress-related diseases. |
| H. Y. Huang, et al\(^{62}\) 2018 | New Zealand White rabbits | Hyaluronic acid | Nanoparticles | Self-assembly method | Large amounts of gelatin-epigallocatechin gallate nanoparticles (GEH-NPs) accumulated in the cytoplasm of human corneal epithelium cells and the ocular surfaces of rats and rabbits, indicating the advantage of GEH NPs for ocular delivery of medication. | GEH NPs are potentially valuable as a new therapeutic agent delivered in eye drops for treating dry eye syndrome. |
| H. Kang, et al\(^{11}\) 2016 | New Zealand albino rabbits | Cyclosporine A | Micelle solutions | Simple method | The number of goblet cells in rabbit conjunctivas after the administration of cyclosporine A-micelle solutions was significantly higher than that with Restasis. | The potential use of a novel MS for the ophthalmic delivery of CsA in treating dry eyes. |
| C. Di Tommaso, et al\(^{163}\) 2011 | Female albino New Zealand rabbits | Cyclosporin A | polymeric micelles | Co-solvent method | After incubation with methoxy poly (ethylene glycol)-hexylsubstituted poly(lactides) (MPEG-hexPLA) micelle formulations, the activation of caspase-dependent and - independent apoptosis as well as autophagy was evaluated using immunohistochemistry for localizing antibodies | MPEG-hexPLA micelles are promising drug carriers for ocular diseases involving the activation of cytokines |
attractive to both academic and pharmaceutical industry researchers working in DED therapeutics.

**Glaucoma**

Glaucoma is the second major cause of blindness world-wide, with a 1% global incidence rate, and a 2% rate in subjects over 45 years old. IOP increases intermittently or continuously in patients with glaucoma, and the dynamic balance in the aqueous circulation is disrupted, causing optic nerve atrophy and visual field defects. The other pathological manifestations of glaucoma are retinal ganglion cell (RGC) apoptosis and chronic progressive degeneration of axons. Two major problems are encountered in the clinic when treating glaucoma, such as low drug bioavailability and poor patient compliance. In last 10 years, studies of drug-loaded nano-technology formulations to treat of glaucoma have shown positive outcomes (Table 3).

Latanoprost has been injected into the subconjunctival space once to evaluate the safety and efficacy of a latanoprost nanoliposome carrier in human eyes (n = 6) diagnosed with either ocular hypertension or primary open-angle glaucoma. No significant irritation was detected after subconjunctival injection of the liposomal latanoprost. A significant reduction in IOP was detected from baseline (27.55 ± 3.25 mmHg) to 1 h later (14.52 ± 3.31 mmHg). More than a 20% IOP reduction was observed after 3-months, which provided evidence for clinical use of liposomal latanoprost in glaucoma therapeutics.

Furthermore, Rodriguez-Aller et al revealed that latanoprost-propylamino-ß cyclodextrin has significant solubility and stability compared with a commercial latanoprost formulation in vitro. Additionally, there is less ocular irritation with a latanoprost-propylamino-ß-CD formulation (9.5%) than that with a commercially marketed formulation of latanoprost (15.5%) in vivo.

Interestingly, acetazolamide has been loaded onto water-soluble mucoadhesive carbosilane dendrimers to evaluate the cytotoxicity and cell viability of dendrimers in normotensive rabbit eyes. The results revealed that G3 (from the third generation of carbosilane cationic dendrimers) cationic carbosilane dendrimers (5 μM) produced a rapid (1 hour post-instillation) and sustained (up to 7-hour) hypotensive effect, reaching a peak 22.6% reduction in IOP.

Visual field loss in patients with glaucoma is caused by death of RGCs. Normal physiological ageing is responsible for an estimated rate of 0.4% RGC loss per year, but this percentage increases to 4% in cases of glaucoma. Considering the complex and multifactorial nature of glaucoma, multiple targets are thought to contribute to the loss of RGCs. The NMDA antagonist memantine loaded in PLGA nanoparticles using the double emulsion solvent evaporation technique significantly reduced loss of RGCs in Morrison’s ocular hypertension rat model.

**Posterior Capsular Opacification**

Postoperative capsular opacification, particularly posterior capsular opacification (PCO), is one of most common complications of cataract surgery. Residual lens epithelial cells (LECs) on the lens capsule lead to proliferation, migration, and trans-differentiation. Various management strategies to control PCO have been tested, including updates on intraocular lens materials and pharmacological treatments. Nano-carrier-loaded targeted drugs or the material method is effective to mechanically prevent the formation of PCO. However, only a few studies have evaluated the use of nanomaterials to prevent PCO. The antimetabolite drug fluorouracil (5-FU) inhibits cell proliferation directly by disturbing the cells’ nucleic acids and proteins. 5-FU is also applied to cure eyes with these characteristics.

To evaluate the effects of 5-FU modified intraocular lens (IOL) to prevent PCO, Huang et al injected 5-FU carried by chitosan nanoparticles into the lens capsule after removing the lens cortex of New Zealand white rabbits during cataract surgery, compared with injecting 5-FU alone. Their findings suggested that 5-FU partially curbs the proliferation of LECs, and the 50% inhibitory concentration (IC50) of 5-FU carried by chitosan nanoparticles was only one-fifth that of direct administration, which significantly lowered damage to the cornea, iris, and ciliary body. In addition, another study found that other cytotoxic drugs, such as daunorubicin and mitomycin C, also inhibit proliferation of LECs, but a suitable method to reduce the toxicity to intraocular tissues is needed. In the future, experiments combining pharmacological treatment of the underlying biological processes and the use of nanomedicine could help prevent PCO.

**Diabetic Cataract**

Cataract is a major cause of vision disorders in the population with diabetes mellitus (DM), and they form much faster in patients with DM than in normal subjects. Oxidative stress.
| Study                          | Experimental Models                  | Drug        | Vehicle/Carriers   | Production Method(s)                      | Results                                                                 | Conclusion                                                                 | Future Direction                                                                 |
|-------------------------------|--------------------------------------|-------------|--------------------|-------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Schnichels S, et al\(^{64}\) 2020 | DBA/2J mice model                     | Travoprost  | Lipid DNA nanoparticle | Self-assembly of DNA amphiphiles          | Travoprost nanoparticles deliver at least twice the amount of the drug at every time-point investigated compared to the pristine drug. | There is applicability of a DNA-based drug delivery system in the field of ophthalmology for the treatment of glaucoma. | In the future, a combination therapy relying on DNA-based NPs and different aptamers might be feasible. |
| Orasugh JT, et al\(^{65}\) 2019 | In vitro gel                         | Pilocarpine | Cellulose nanocrystals | Acid hydrolysis process                   | Have higher sustained drug release and less toxicity.                    | Cellulose nanocrystals have a significant effect on the gelation behavior, gel strength, and drug release kinetics of poloxamer copolymer-cellulose nanocrystals formulations. | Unspecified                                                                      |
| Sánchez-López E, et al\(^{63}\) 2018 | Morrison’s ocular hypertension model in Dark Agouti (DA) rats | Memantine | PLGA nanoparticles | Modification of the double emulsion solvent evaporation technique | Well tolerated in vitro (human retinoblastoma cells) and in vivo (Draize test); Reduced RGC loss in vivo. | Topical MEM-NP is safe, well tolerated, and, most promisingly, neuroprotective in an experimental glaucoma model. | Unspecified                                                                      |
| Fahmy HM, et al\(^{64}\) 2018 | White albino rabbits                 | Latanoprost | Liposomes           | Film hydration method                     | Reduced the IOP in glaucomatous white albino rabbits, which lasted for 8 hours. | Lip (LAT + TQ) and Lip (LAT) were the most effective tested formulations, which provided in vivo sustained drug release and showed the maximum IOP lowering effect up to 84 h as compared to other tested formulations. | None of the prepared liposome formulations succeeded in improving the glaucoma-induced oxidative stress damage. |
| Wang F, et al\(^{67}\) 2018    | White New Zealand rabbits            | Brinzolamide | Nanoliposomes       | Thin-film dispersion method               | Reduced IOP in less than 1 hour, reached peak efficacy at 2 hours, and sustained release effect for 12 hours. | The HP-β-CD/BRZ loaded nanoliposomes might have a promising future as a NODDS for glaucoma treatment. | Further studies are still required to investigate the in vitro release properties of BCL and elucidate how the release profile affects the therapeutic efficacy of BCL. |
| Author(s) | Year | Species | Drug Formulation | Method | Effects | Notes |
|-----------|------|---------|------------------|--------|---------|-------|
| Tan G, et al | 2017 | New Zealand albino rabbits | Timolol maleate | Chitosan coated liposomes | Ammonium sulfate gradient coupled with a pH-gradient | Significantly reduced the IOP | CHL is a potentially useful carrier for ocular drug delivery, which could improve the efficacy of TM. The formulation reported here will be the subject of future studies aimed at improving its clinical use. |
| Rathod LV, et al | 2017 | Goat eyes and albino rabbits | Acetazolamide | Nanoparticles | Solvent displacement method | Displayed better permeability and flow across corneal tissue in vitro | The nanoparticles impregnated ocular inserts can act as potential platform for delivering drug to posterior segment of eye not only for glaucoma but also for other eye diseases. |
| Ikuta Y, et al | 2017 | Male Sprague-Dawley rats | Brinzolamide | Nanoparticles | Reprecipitation method | Increases the eye penetration rate and resulted in high drug efficacy | The nano-eye-drops may have applications as a next-generation ophthalmic treatment. |
| Kouchak M, et al | 2016 | Albino rabbits | Dorzolamide hydrochloride | Nanoliposomes | Reverse-phase evaporation vesicle method | Had greater IOP lowering activity and more prolonged effects | It could be a candidate for the treatment of ocular hypertension. Assay of DRZ in aqueous humor following drug instillation into rabbit eye should be done before clinical trials as well. |
| Bravo-Osuna I, et al | 2016 | New Zealand white rabbits | Acetazolamide | Dendrimers | Hydroxysilylation of Boc-protected allylamine and followed by deprotection with HCl | Demonstrated rapid (1 hour post-instillation) and sustained (up to 7 hours) hypotensive effect, reaching a peak 22.6% IOP reduction in normotensive rabbit eyes | Carbosilane dendrimers can be used in a safe range of concentrations to enhance the bioavailability of drugs topically administered in the eye. |
| Yu S, et al | 2015 | New Zealand rabbits | Timolol maleate | Liposome | pH-gradient method | Reduced the IOP and the effective time was significantly longer | Liposome incorporated ion sensitivity in situ gels has a potential ability for ophthalmic delivery. Future work will research the pathway and mechanism of the cellular uptake of TM L-ISG. |
| (Continued) |
| Study | Experimental Models | Drug | Vehicle/Carriers | Production Method(s) | Results | Conclusion | Future Direction |
|-------|---------------------|------|------------------|----------------------|---------|------------|------------------|
| Rodriguez-Aller M, et al<sup>96</sup> 2015 | New Zealand rabbits | Latanoprost | Cyclodextrins | Unspecified | Improved solubility and stability in vitro. In vivo evaluation of ocular tolerability revealed that ocular irritation was 15.5% with the commercially marketed formulation of latanoprost and 9.5% with the latanoprost-propylamino-β-CD formulation. | The latanoprost-propylamino-β-CD formulation was demonstrated to successfully address the main stability, solubility, and tolerance limitations of topical ocular latanoprost therapy for glaucoma. | Unspecified |
| Wong TT, et al<sup>97</sup> 2014 | Human | Latanoprost | Nanoliposome | Gradient method | Good tolerance with no evident safety issues or adverse events. | | |
| Singh J, et al<sup>72</sup> 2014 | Rabbits model | Acetazolamide | Polymeric nanoparticles | Nanoprecipitation method | Sustained release effects and increased transcorneal permeation in vivo. | NP-ISG5 may offer intensive management of glaucoma via higher permeation, prolonged preocular residence time and sustained drug release along with higher in vitro efficacy, safety and patient compliance. | These systems are emerging as vehicles for the treatment of diseases of posterior portion of eye which is not possible by topical delivery through conventional systems. |
| Tuomela A, et al<sup>73</sup> 2014 | Wistar rats | Brinzolamide | Nanocrystal | Top-down wet milling technique | The IOP lowering effect was investigated using a modern rat ocular hypertensive model and elevated IOP reduction was seen in vivo with all the formulations. The reduction achieved in experimentally elevated IOP was comparable to that obtained with a commercial product. | Various BRA nanocrystal formulations which all showed advantageous dissolution and absorption behavior were successfully formulated. | Unspecified |
| Authors          | Year  | Species          | Drug               | Formulation                                                                 | Drug Distribution                                                  | Conclusion                                                                 |
|------------------|-------|------------------|--------------------|-----------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------------|
| Mishra V, et al  | 2014  | New Zealand albino rabbits | Acetazolamide      | Poly(propylene imine) dendrimer nanoarchitectures                          | Unspecified                                                         | The sustained and prolonged reduction in IOP suggested that drug entrapped in dendrimers can be used for higher retention in ocular cul-de-sac. |
| Jung HJ, et al   | 2013  | Beagle dogs      | Timolol            | Nanoparticles of PGT (propoxylated glyceryl triaclylate)                    | Thermal polymerization of a mixture of timolol base and PGT.        | The PPI dendrimer based formulation seems to enhance the ocular drug residence time and exhibits better intraocular pressure lowering effect for glaucoma treatment. |
| Wu W, et al      | 2013  | New Zealand rabbits | Brinzolamide       | Liquid crystalline nanoparticles                                            | Modified emulsification method                                      | Further in vivo safety and pharmacokinetics and pharmacodynamics tests particularly with lenses in which particles are loaded prior to lens fabrication are necessary to evaluate the potential of the proposed approach for glaucoma therapy. |
| Natarajan JV, et al | 2012 | New Zealand White rabbits | Latanoprost        | Egg PC liposomes                                                           | Hydration method                                                   | A single injection of latanoprost-loaded Egg PC liposomes can lower the IOP for up to 90 days, with a greater IOP lowering effect than daily topical administration of latanoprost. |

Further detailed studies on the pharmacodynamics of these liposomes within the ocular tissues will determine its future potential clinical application.
affects the pathogenesis of cataract induced by hyperglycemia. Over the past 10 years, efforts have been made to develop nano-based formulations involving antioxidative stress control to treat diabetic cataract.

Cerium, an earth element in the lanthanide series, has oxidation states of Ce$^{3+}$ and Ce$^{4+}$, which scavenge free radicals. Yang et al prepared cerium (III) chloride (CeCl$_3$)-loaded mesoporous silica (CeCl$_3$@mSiO$_2$) nanoparticles and revealed their application for treating diabetes-associated cataract in vitro and in vivo using the streptozotocin (STZ)-induced male Wistar diabetic rat cataract model (Figure 4). Furthermore, Zhou et al synthesized cerium oxide nanoparticles (CeO$_2$-NPs) coated with PEG-PLGA (PCNPs) using the emulsification method, and reported that it protects LECs from oxidative stress damage by scavenging reactive oxygen species (ROS) and attenuating alpha-crystalline glycation in the STZ-induced diabetic rat model.

These findings have opened avenues for developing potential therapeutic strategies to treat diabetic cataract.

Figure 4 Cerium (III) chloride (CeCl$_3$)-loaded mesoporous silica (CeCl$_3$@mSiO$_2$) nanoparticles. A type of cerium (III) chloride (CeCl$_3$)-loaded mesoporous silica (CeCl$_3$@mSiO$_2$) nanoparticles designed and to prevent the formation of diabetic cataract in vitro and in vivo using a well-established rat model of streptozotocin-induced diabetes. (A) Schematic diagram of CeCl$_3$@mSiO$_2$ nanoparticle preparation; (B) The morphology of the mSiO$_2$ nanoparticles under transmission electron microscopy (spherical, uniform and monodisperse morphology with an average diameter of 85 nm); (C) A line graph, showing the time course of changes in the cataract degrees in different groups of animals; (D) various degrees of cataract and representative images of H&E-stained sections of the lens tissue in experimentally induced diabetic animals 8 weeks after treatment with vehicle or 10 and 20 mg/kg CeCl$_3$@mSiO$_2$ nanoparticles, respectively. Reprinted from Nanomed, 13, Yang J, Gong X, Fang L, et al. Potential of CeCl$_3$@mSiO$_2$ nanoparticles in alleviating diabetic cataract development and progression, 147–1155, Copyright 2017, with permission from Elsevier.
Notably, administering these nanoparticles is invasive, as CeCl₃@mSiO₂ nanoparticle is an intraperitoneal injection,¹⁰ and PCNP is a subconjunctival injection.¹¹ Therefore, studies are necessary to optimize potential non-invasive nanotechnology-based DDS to prevent diabetic cataract.

**Diabetic Retinopathy**

Diabetic retinopathy (DR) is one of the most common microvascular complications of DM, and is the main cause of blindness in the working-age population. The pathological mechanisms of DR include hyperglycemia and lipid disorder.¹¹² Quercetin has been isolated from leaves and grains, and is reported to have anti-diabetic activities. Thus, quercetin has been traditionally used to treat DM and its complications.¹¹³ However, poor bioavailability and multiple biological interactions are the major challenges of phytomedicines.¹¹⁴ Wang et al reported that intravitreal injection of quercetin coated with a freeze-dried nano-formulation had significant therapeutic effects against DR, and reduced lipid peroxidation in a zebrafish model, one of the disadvantages of nano-formulations is that they do not achieve target cell specificity.¹¹⁵ Therefore, Wang et al used cell-specific promoters to deliver specific retinal cell types, such as retinal pigment epithelium, rod cells, cone cells, and ganglion cells, using liposome-protamine-DNA complex (LPD)-mediated gene delivery loaded in lipid-based nanoparticles by a two-step packaging technology employing a multilayering method.¹¹⁶ These findings indicate that peptide-modified LPD nanoparticles can be delivered for ocular gene therapy of retinal diseases including DR.

**Age-Related Macular Degeneration**

Age-related macular degeneration (AMD) is a major cause of blindness in the developed world and choroidal neovascularization (CNV) and geographic atrophy are serious and potentially devastating complications of the disease.¹¹⁷ Many studies have shown that nano-carrier DDSs have potential to treat AMD (Table 4). However, these studies are still in the preliminary stage. Therefore, further studies are needed to develop novel formulations. Unlike anterior segment drugs, posterior segment drugs must overcome several ocular barriers before reaching the target site. For example, anti-VEGF drugs are given through an intravitreal injection, and even though the delivery is of small therapeutic molecules, there is still poor permeability. Nano-carrier DDSs improve the permeability of therapeutic agents across biological membranes and benefit therapeutics of CNV of the eye using both invasive and non-invasive techniques.¹¹⁸ Nanomedicine targets delivery and binds with the CNV site, and prolongs the release time of the therapeutic agent.

Kringle 5 (K5) is a natural anti-angiogenic peptide and a proteolytic fragment of plasminogen with a length of 80 amino acids. However, its anti-angiogenic effect is short-lived due to the short half-life of the K5 peptide in the vitreous and retina. K5 nanoparticles containing the K5 plasmid mediate continuous expression of K5 in the retina for up to 4 weeks. Jin et al used K5-carrying PLGA nanoparticles (K5-NP) to observe their effect on laser-induced CNV in rats. The results showed that K5-NP mediated the continuous expression of K5 in the retina (primarily in the inner retina) for up to 2 weeks. Interestingly, there was also high expression of K5 in the outer retina at the laser photocoagulation site. Intravitreal injection of K5-NP reduced the area of CNV, reduced the permeability of retinal blood vessels and the high expression of VEGF, and downregulated the expression of inflammatory factors, such as TNF-α and ICAM-1, and even weakened β-catenin aggregation. These results suggest that K5 has anti-inflammatory activity, and that K5-NPs have a sustained inhibitory effect on CNV.¹¹⁹

Very few studies have been conducted on treating AMD with nanotechnology in the past 5 years, and this should inspire more attention from researchers in the future.

**Retinopathy of Prematurity**

Retinopathy of prematurity (ROP) is a type of proliferative retinopathy that occurs in premature infants and low-weight infants. Premature birth can cause the retina to be exposed to a high partial pressure oxygen environment. The relative hypoxia generated in the body promotes the release of VEGF, which induces retinal angiogenesis, vitreous hemorrhage, and traction retinal detachment, leading to preventable causes of childhood blindness.¹²⁰ A nanocarrier DDS has been developed for ROP in the last decade. In the study by Kim et al, gold was loaded onto nanoparticles and exhibited anti-VEGF-induced angiogenesis through blocked autophosphorylation of VEGF receptor-2 to inhibit extracellular signal-regulated kinase (ERK) 1/2 activation in a ROP mouse model.¹²¹

**Retinoblastoma**

Retinoblastoma (Rb) is one of the most common malignancies of children. Current therapeutic strategies for
| Study                  | Experimental Models                          | Drug          | Vehicle/ Carriers | Production Method(s) | Results                                                                 | Conclusion                                                                 | Future Direction                                                                 |
|-----------------------|---------------------------------------------|---------------|-------------------|----------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Tang M, et al, 2018   | An Alkali-Burn Corneal Neovascularization Model in the Mouse | Silicon       | Nanoparticles     | Photochemical method. | SiNPs-RGD features efficacious antiangiogenic ability; SiNPs-RGD can label angiogenic blood vessels and has neovascularization suppression effects. | the SiNPs-RGD as a novel class of high-quality theranostic probe is suitable for simultaneous diagnosis and treatment in ocular neovascular diseases | Unspecified                                                                     |
| Wang Y, et al, 2016   | Balb/c mice and Sprague-Dawley rats          | LPD-mediated gene delivery | Lipid-based nanoparticles | A two-step packaging technology employing a multilayering method | Cell-specific promoters enable lipid-based nanoparticles to deliver genes to specific retinal cells in vivo. | This work will inspire investigators in the field of lipid nanotechnology to couple cell-specific promoters to drive expression in a cell- and tissue-specific manner. | The formulated lipid nanoparticles may be appropriate for use with other tissues for the purposes of gene delivery with tissue-specific promoters. |
| Huu VA, et al, 2015   | Sprague-Dawley rats                          | Nintedanib    | Nanoparticle      | Light-sensitive polymer | Stably retain encapsulated molecules in the vitreous; released cargo in response to UV exposure up to 30 weeks post-injection; light-triggered release of nintedanib 10 weeks post-injection suppresses CNV in vivo. | Light-sensitive nanoparticles are biocompatible and cause no adverse effects on the eye as assessed by electoretinograms (ERG), corneal and retinal tomography, and histology. | Whether light can trigger release of multiple therapeutic doses of BIBF120. |
| Luo L, et al, 2013    | C57BL/6J mice and Cynomolgus macaque monkeys | RGD- targeted | PLGA nanoparticles | Emulsion solvent evaporation method | Improved with nearly 40% restoration of visual loss induced by CNV. | These findings offer a nanoparticle-based platform for targeted, vitreous-sparing, extended-release, nonviral gene therapy. | Further studies would be necessary before concluding this delivery system is completely safe. |
| Authors          | Animals/Mice                     | Drug/Agent | Particle Material | Method                        | Outcome/Results                                                                 | Remarks/Conclusion                                                                                                                                 |
|------------------|----------------------------------|------------|-------------------|-------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Iwase T, et al   | Pathogen-free C57BL/6 mice and Dutch belted rabbits | Doxorubicin | Poly(sebacic acid)-polyethylene glycol nanoparticles | Oil-in-water emulsion method | Reduced HIF-1-responsive gene products, strongly suppressed CNV, and no retinal toxicity; suppressed NV for at least 35 days in vivo; sustained release in vivo for at least 105 days. | A novel HIF-1-inhibitor-polymer conjugate formulated into controlled-release particles maximizes efficacy and duration of activity, minimizes toxicity, and provides a promising new chemical entity for treatment of ocular NV. |
| Kyosseva SV, et al | Mutant mice with targeted deletion of the Vldlr gene | Cerium oxide | Nanoparticles | Simple wet chemistry methods | Many cell signaling, cellular development, growth and proliferation, and tissue development were affected; inhibited the activation of ERK 1/2, JNK, p38 MAP kinase, and Akt. | Nanoceria may represent a novel therapeutic strategy to treat AMD, RAP, and other neurodegenerative diseases. |
| Yandrapu SK, et al | Rat model | Bevacizumab | PLGA nanoparticles | Emulsion solvent evaporation method | In vitro release of bevacizumab from NP in PMP was sustained for 4 months. | NP in PMP is a novel sustained release system for protein drugs to reduce frequency of protein injections in the therapy of back of the eye diseases. |
| Jo DH, et al     | C57BL/6 mice | Silicate | Nanoparticles | Reverse microemulsion method | No direct toxicity; reduced anomalous retinal angiogenesis in vivo; inhibited in vitro VEGF-induced angiogenesis via suppression of VEGF receptor-2 phosphorylation and blocking ERK 1/2 activation. | SiNPs could be an inhibitor of the potency and safety of retinal neovascularization that is mediated by VEGF. Biodegradation and biodistribution of NPs might be investigated before clinical application. |

(Continued)
| Study | Experimental Models | Drug | Vehicle/Carriers | Production Method(s) | Results | Conclusion | Future Direction |
|-------|---------------------|------|-----------------|---------------------|---------|------------|-----------------|
| Iezzi R, et al (2012) | Royal College of Surgeons (RCS) rat retinal degeneration model | Hydroxyl-terminated polyamidoamine | Nanodevices | Unspecified | Sustained release effects over 90 days. One intravitreal injection of 1 mg of FA conjugated to 7 mg of the dendrimer was able to arrest retinal degeneration, preserve photoreceptor outer nuclear cell counts, and attenuate activated microglia, for an entire month. | PAMAM dendrimers (with no targeting ligands) have an intrinsic ability to selectively localize in activated microglia, and can deliver drugs inside these cells for a sustained period for the treatment of retinal neuro-inflammation. | This approach can have significant implications in the treatment of neuro-inflammation in other neurodegenerative diseases such as cerebral palsy, autism, and Alzheimer’s disease. |
| Liu HA, et al (2011) | Brown-Norway rats | PEGylated liposome-protamine-hyaluronic acid nanoparticles (PEG-LPH-NP) loaded with siRNA (PEG-LPH-NP-S) | Liposome-polymer hybrid nanoparticles | Post-insertion method | Protected siRNA load and facilitated the intracellular delivery of siRNA, the expression inhibition of VEGFR1, and the reduction of CNV area in vivo. | PEG-LPH-NP may be a promising lipid nanoparticle system for the siRNA treatment of CNV. | Unspecified |
| Jin J, et al (2011) | Brown Norway rats | Plasminogen kringle | PLGA nanoparticle | Emulsion–diffusion–evaporation technique with some modifications | Intense K5 expression was detected in the retina 2 weeks after the injection of K5-NP. Areas of CNV were significantly decreased in the K5-NP treatment group compared with that in the control-NP group. The K5-NP injection also significantly reduced vascular permeability. | K5 has a novel anti-inflammatory activity. K5-NP mediates a sustained inhibitory effect on CNV. | The receptor and signaling pathway mediating the anti-inflammatory activity of K5, however, remains to be defined. |
| Zhang C, et al (2010) | Brown Norway rats | PshHIF-1α | PLGA nanoparticle | Water-in-oil-in-water (W/O/W) multiple emulsion technique | Expression of GFP preferentially localized in the retinal pigment epithelium cell layer and lasted for 4 weeks; reduced the mean thickness of the CNV lesions in vivo. | pshHIF-1α NPs may act as a novel therapeutic option to transfer specific pDNA and inhibit the formation of experimental CNV. | The efficacy of this method is not clear yet and needs further determination. |

**Abbreviations:** IOP, intraocular pressure; AMD, age-related macular degeneration; RAP, retinal angiomatous proliferation; CNV, choroidal neovascularization.
advanced Rb include the use of chemotherapeutic agents, such as topotecan. Nevertheless, the efficacy of topotecan in the treatment of advanced Rb is unsatisfactory. Additionally, the side-effects of long-term anticancer therapy on the health of children cannot be ignored. Consequently, preparing a novel sustained-release formulation of chemotherapeutic agents is of great importance. Qu et al produced topotecan-loaded mesoporous silica nanoparticles with folic acid conjugated on the surface to achieve superior anticancer efficacy (58%) in human retinoblastoma cells (Y79). Further in-vivo experiments by Delrish proved this finding. In that study, thiolated chitosan nanoparticles were used to encapsulate topotecan and develop an intraocular tumor chemotherapeutic drug carrier with improved biocompatibility, controlled release, targeted delivery, and enhanced physical stability. 

**Optic Neuropathy**

Optic neuropathy is characterized by the loss of axons in the optic nerve and retina, followed by death of RGCs, resulting in irreversible blindness. RGCs are responsible for signal transmission from the retina to the brain and their death through apoptosis causes visual impairment. The mechanistic target of rapamycin (mTOR) pathway plays a critical role in the health and disease status of the retina and optic nerve. RGC damage is modulated by rapamycin through the mTOR pathway. Therefore, combining mTOR pathway stimulating biologics to protect RGCs would provide better control over cell pathway modulator delivery, release, clearance, and residency time. Eriksen et al prepared two liposome formulations using the film hydration method. Liposome aqueous cores were loaded with ciliary neurotrophic factor (CNTF) and insulin-like growth factor-I (IGF), while liposome membranes were loaded with the lipid-conjugated osteopontin peptide (OPP) and either production of anthocyanin pigment 2 (PAP2) or production of anthocyanin pigment 4 (PAP4). Finally, Eriksen et al found that these liposomes promoted neuroprotection by stimulating the mTOR pathway after a single injection in an N-methyl-d-aspartic acid mouse model with extensive retinal damage. Their findings demonstrated significant experimental upregulation of mTOR signaling promoting RGC survival and axon regeneration after an optic nerve crush injury. 

**Uveitis**

The uvea is composed of the iris, the ciliary body, and the choroid. Inflammation in any part of the uvea can be defined as uveitis. According to the main anatomical sites of ocular inflammation, uveitis can be further divided into anterior, intermediate, posterior, and panuveitis. Anterior uveitis is the main site of inflammation in the anterior segment (iris and ciliary body). Intermediate uveitis is defined as inflammation of the vitreous cavity and serrated margin. Posterior uveitis involves the retina and choroid. Inflammation in panuveitis includes all layers. The main symptoms of uveitis are scleral hyperemia, pain, and visual impairments. Treatments for uveitis include the application of anti-inflammatory and corticosteroids alone or in combination with other immunosuppressive agents.

There is increasing interest in inducing positively charged nanocarriers by coating PLGA nanoparticles, cubosomes/cubosomal gels, or PVCL-PVA-PEG nanomicellar and cationic nanostructured lipid carriers (Table 5). Most recently, the water-insoluble corticosteroid triamcinolone acetonide (TA) was loaded onto cationic, nanostructured lipid carriers to treat anterior uveitis. The outcomes indicated that encapsulation of TA in the cationic lipid nanocarriers increases corneal penetration without increasing toxicity and increases the drug’s bioavailability within the eye. Similar safety and efficiency were found in an evaluation of a topical nanomicellar formulation for the immunosuppressant drug everolimus. In that study, everolimus loaded positively charged Soluplus®, a grafted copolymer of polyvinyl caprolactam-polyvinyl alcohol-polyethylene glycol (PVCL-PVA-PEG) of 65.55 nm, was used to improve permeability through ocular epithelia with minimal or no irritation resulting in enhanced ocular bioavailability to treat posterior uveitis.

Cubosomes are lipid-based nanoparticles in which the membranes are entangled into a complex array of pores arranged in a cubic lattice. Compared with liposome analogs, these complex nanoparticles encapsulate a large amount of drug. The cubosomes were nanosized (100 to 278 nm) with high encapsulation efficiency (94 ± 4.7%) of the lipophilic drug beclomethasone dipropionate. Transcorneal permeation and IOP measurement data suggested significant controlled release, enhanced corneal permeability, and greater relative bioavailability from cubosomes and the Cubo-gel in vitro. Furthermore, superior anti-inflammatory properties were recorded for the Cubo-gel to treat endotoxin-induced posterior uveitis in a rabbit model.
| Study                  | Experimental Models | Drug            | Vehicle/Carriers | Production Method(s) | Results                                                                 | Conclusion                                                                 |
|-----------------------|---------------------|-----------------|------------------|----------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Nikita, et al<sup>32</sup> 2021 | Unspecified         | Everolimus      | PVCL-PVA-PEG nanomicellar | Unspecified          | Have high encapsulation efficiency and sustained release of everolimus; have higher permeation across goat cornea than everolimus suspension. | Everolimus nanomicelles could be considered a promising topical drug delivery nanocarrier for treating uveitis. |
| Garg V, et al<sup>88</sup> 2021 | Endotoxin-Induced Uveitis in Rabbit | Tacrolimus       | Proglycosome nano-vesicles | Propylene glycol modified lipid vesicles | PNV treatment not only subsides clinical symptoms of uveitis but also prevents breakdown of blood aqueous barrier. | Tacrolimus loaded PNVs are a potential new topical treatment for uveitis. |
| Gaballa SA, et al<sup>134</sup> 2020 | Rabbits' model | Beclomethasone Dipropionate | Cubosomes/Cubosomal Gels | Top-down technique | Transcorneal permeation parameters Papp, flux and AUC0-10h, were markedly enhanced up to 4-, 5.8- and 5.5-fold, respectively. | Cubosomes/Cubo-gel could be an auspicious ocular delivery system for BDP that was able to effectively treat uveitis. |
| Nirbhavane P, et al<sup>131</sup> 2020 | LPS induced inflamed cells | Triamcinolone acetonide | Cationic nanostructured lipid carriers | Hot microemulsion method | Sustained release effects in vitro; no cytotoxicity; retained inside the cells for 24 h; reduced the TNF-α level in LPS induced inflamed cells. | cTA-NLC could be a promising option for the topical treatment of uveitis. |
| Coburn PS, et al<sup>189</sup> 2019 | A murine sterile endophthalmitis model | Gatifloxacin | Rabbit nanosponges | Biomimetic erythrocyte-derived nanoparticle | Reduced the hemolytic activity of a diverse array of PFTs; human nanosponges alone protected mouse retinas following intraocular infection with E. faecalis and S. pneumoniae but not B. cereus or MSSA. | Clinical improvements in intraocular infections following nanosponge treatment were dependent on the complexity and types of toxins produced. Nanosponges might serve as an adjunctive therapy for the treatment of ocular infections. |
| Chennamaneni SR, et al<sup>190</sup> 2013 | New Zealand White (NZW) rabbits | Dexamethasone | PLGA nanoparticles | Standard oil-in-water (o/w) emulsion-solvent extraction method | DXM flow was bidirectional in the endocapsular space and it was found in the anterior and posterior chambers after up to 6 weeks after WHAT?. | The feasibility of drug delivery from the capsular bag to the anterior and posterior segments effectively compared to topical alternatives. |
| Elbialy NS, et al<sup>191</sup> 2013 | Male New Zealand white rabbits | Prednisolone acetate | Liposomes | Film hydration method | Have higher entrapment efficiency and slower release rate; higher concentration of PSA in aqueous humor. | pSUV and pMLV are effective carriers for PSA and have a good potential as drug delivery systems in the ocular therapy. |
Vitreous Opacities
Myopia and aging are the main causes of progressive aggregation of vitreous collagen, leading to vitreous opacity and severely affecting vision. The main complaint of vitreous opacity is the visual phenomenon of “floating view”. As nanomedicine-based therapeutic solution can locally ablate “floaters” and highly reduce light energy, compared with traditional YAG laser therapy. Sauvage et al proposed hyaluronic acid (HA)-coated gold nanoparticles to localize them with greatly reduced light energy. In that study, the collagen aggregates were destroyed with approximately 1000 times less light energy after applying nanosecond laser pulses than typically used for YAG laser therapy, indicating that applying the laser to ablate the plasmonic nanoparticles conjugated with the vitreous opacity was a safer, faster, and more reliable treatment for eye diseases.

Anti-VEGF Agents and Novel Strategies Based on Nanotechnology
Biopharmaceuticals and biotechnological therapeutics for treating angiogenesis in ocular disease are mainly based on intravitreal injection of anti-VEGF agents. The intravitreally injected anti-VEGF drugs improve visual acuity and macular morphology in most patients with pathological ocular angiogenesis, such as CNV, proliferative diabetic retinopathy, ROP, and neovascular glaucoma. The VEGF inhibitors aflibercept, bevacizumab, conbercept, pegaptanib, and ranibizumab are approved treatments for certain eye diseases that occur particularly in the elderly and bevacizumab is usually used “off-label” in clinical practice. Due to the limited residence time of anti-VEGF drugs in the vitreous body, monthly intravitreal injections of these agents are recommended with 3-monthly loading dose injections followed by individualized therapy with “pro re nata” (PRN) or “treat and extend” (T&E) regimens. However, repeated intravitreal injections increase the risk for adverse systemic and ocular effects of the anti-VEGF drugs, including a hypertensive crisis, ischemic stroke, retinal detachment, hemorrhage, cataract, or endophthalmitis. Therefore, strategies to reduce the frequency of intraocular injections of these anti-VEGF agents and extend their residence time in the vitreous body are still needed. The ocular residence time and release time of anti-VEGF medication is related to (1) the molecular size, (2) the formation of molecular conglomerates and (3) the presence of crystallizable fragments. Several nano-carriers have been used to load anti-VEGF drugs for sustained drug release, thereby minimizing the number of intravitreal injections required. To date, many efforts have been focused on the development of nano-carriers for bevacizumab and ranibizumab, which have demonstrated sustained release effects in vitro and a notably increased antiangiogenic efficacy of pathological ocular angiogenesis in vivo when both formulations are administered via intravitreal injection (Table 6). Furthermore, polymeric nanoparticles enhance permeation after surface modification with a cationic polymer. Recent advances in nanotechnology have offered many promising opportunities as an ocular anti-VEGF delivery system for pathological angiogenic ocular diseases.

Nanotechnology and Ophthalmic Drug Delivery System: Current Challenges
Ocular nano-carrier DDSs are particularly versatile, as there has been tremendous progress improving drug stability, solubility, corneal permeability, and retention time, as well as increasing bioavailability and efficacy, but the exact mechanism of action, quality control, and safety evaluation deserve further attention. Notably, the vehicles used for nano-carrier DDSs should be further evaluated. For example, the toxicity of excipients and pollutants has been evaluated in vitro, while the inflammatory reaction has been evaluated in vivo. Additionally, the size of the mouse lens is quite different from that of humans; thus, drug permeability from the cornea to the target in the retina may be converse. Furthermore, the difficulty is to achieve efficient delivery of drugs to the posterior segment of the eye through non-invasive means. Moreover, the current research trend is to design and synthesize new carrier materials or use two or more methods to prepare composite systems.

Liposomes
Many problems have developed when applying liposome preparations in ophthalmology, such as low drug loading, leakage of embedded drugs, poor long-term stability, high cost of industrialized large-scale production, difficulty with sterilization, and relatively low formulation targeting. Moreover, the retention time of simple liposomes in the eye is not ideal, so the development of new liposome preparations is necessary.
| Study | Experimental Models | Disease | Drug | Vehicle/Carriers | Production Method(s) | Results | Mean Particle Size (nm) | Future Direction |
|-------|---------------------|---------|------|------------------|----------------------|---------|------------------------|-----------------|
| Formica ML, et al 2021 | HUVEC | Neovascular ocular pathologies | Bevacizumab and triamcinolone | Lipid mix and stabilizers | Phase inversion temperature | Enhanced antiangiogenic properties in HUVEC | 113–182 | Merit future investigation to validate and improve clinical use in treating AMD and other angiogenesis-dependent diseases. |
| Liu J, et al 2019 | Rabbit model | CNV | Bevacizumab and dexamethasone | PLGA nanoparticles | Emulsion solvent evaporation | Sustained release effects in vitro; enhanced inhibitory effect on tube formation and VEGF secretion in HUVEC; increased antiangiogenic effect of CNV in a rabbit model. | 190–222 | Sustained release effects in vitro; enhanced efficacy inhibiting tube formation and VEGF secretion in HUVEC; enhanced antiangiogenic property in vivo. |
| Sun JG, et al 2019 | Mice model | Corneal neovascularization and oxygen-induced retinopathy | Bevacizumab | Mesoporous silica nanoparticles | Nanocasting | Sustained release effects in vitro; enhanced antiangiogenic efficacy in vivo. | 140 | Sustained release effects in vitro; enhanced efficacy as antiangiogenic in vivo. |
| Sun CL, et al 2019 | Rabbit model | DR | Bevacizumab | Chitosan grafted polyethylene glycol | Double crosslinking (ionic and covalent) process in reverse emulsion | Sustained release effects in vitro; enhanced efficacy at high intravitreal drug concentration after subtenon injection in vivo. | 200–900 | Further studies are warranted to evaluate the stability of antibody-loaded nanoparticles and the anti-angiogenesis of bevacizumab loaded nanoparticles. |
| Ugurlu N, et al 2019 | Rabbit model | Eye posterior segment neovascularization | Bevacizumab | Chitosan nanoparticles | Ionic gelation | Sustained release effects in vitro; enhanced efficacy at high intravitreal drug concentration after subtenon injection in vivo. | 188 | Further studies are warranted to evaluate the stability of antibody-loaded nanoparticles and the anti-angiogenesis of bevacizumab loaded nanoparticles. |
| Authors            | Model                    | Solution Type                  | Polymer/Component                | Processing Method                          | Characteristics                                                                                      | Duration | Notes           |
|--------------------|--------------------------|--------------------------------|----------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------------|----------|-----------------|
| Luis de Redín I, et al<sup>50</sup> 2019 | Corneal neovascularization | Rat model                       | Bevacizumab                      | Human serum albumin nanoparticles           | Desolvation followed by freeze-drying; sustained release effects in vivo; formulation remained in eye for more than 4 hours post-topical administration; improved antiangiogenic efficacy in vivo. | 310      | Unspecified     |
| Juan M. Llabot, et al<sup>95</sup> 2019 | Corneal neovascularization | Unspecified                     | Bevacizumab and suramin          | Human serum albumin nanoparticles           | Desolvation; sustained release effects in vivo; bevacizumab released from Nps-Ga was characterized by a small burst effect followed by a sustained release rate. | 158–210  | Unspecified     |
| Zhang XP, et al<sup>196</sup> 2018   | Oxygen-induced retinopathy and corneal neovascularization | Mice model                      | Bevacizumab                      | PLGA-nanoparticles                          | Double-emulsion solvent evaporation; sustained release effects in vitro; increased half-life of drug and enhanced antiangiogenic efficacy in vivo; enhanced antiangiogenic properties in HUVEC. | 133      | Unspecified     |
| Yan J, et al<sup>197</sup> 2018      | Neovascular age-related macular degeneration | Human umbilical vein endothelial cells | Ranibizumab                     | Ring opening polymerization, following addition of iron oxide nanoparticles | PLGA-PEGylated magnetic nanoparticles; inhibition of the tube formation in HUVEC. | 5–10     | Unspecified     |
| D. K. Karumanchi, et al<sup>198</sup> 2018 | Unspecified              | Rabbit model                    | Bevacizumab                      | Phospholipids and lipids of different chain size | Lipid hydration and extrusion; sustained release effects in vivo; slow release and retained antibody activity after intravitreal administration in vivo. | 120–385  | Unspecified     |
| Mu H, et al<sup>199</sup> 2018       | CNV                      | Rabbit model                    | Bevacizumab                      | Phospholipids and lipids of different chain size, albumin and PVA | Double emulsification; sustained release effects in vivo; prolonged residency time in eye after intravitreal injection in vivo; enhanced antiangiogenic efficacy in a laser-induced CNV. | 1190–4360 | Unspecified     |

(Continued)
| Study                | Disease                                      | Experimental Models | Drug          | Vehicle/ Carriers                  | Production Method(s)                  | Results                                                                                           | Mean Particle Size (nm) | Future Direction                                                                                   |
|---------------------|----------------------------------------------|---------------------|---------------|-----------------------------------|---------------------------------------|--------------------------------------------------------------------------------------------------|------------------------|--------------------------------------------------------------------------------------------------|
| Pandit J, et al<sup>200</sup> 2017 | VEGF related retinal disease                 | Goat and pig       | Bevacizumab   | Chitosan-coated PLGA nanoparticles | Emulsion-solvent evaporation          | Increased drug transscleral permeation; enhanced bioadhesion in vivo.                             | 222                    | Further studies concerning the cytotoxicity and concentration dependent reduction of the VEGF concentration in DR model were underway. |
| Sousa F, et al<sup>200</sup> 2017 | VEGF related retinal disease                 | HUVEC               | Bevacizumab   | PLGA-nanoparticles                | Double-emulsion solvent evaporation   | Sustained pH-dependent bevacizumab release in vitro.                                              | 198                    | The mechanisms underlying bevacizumab delivery at the sub-cellular level are certainly needed.   |
| Elsaid N, et al<sup>202</sup> 2016 | Macular diseases                             | HUVEC               | Ranibizumab   | PLGA microparticles entraping chitosan nanoparticles | Chitosan crosslinking - modified double emulsion method | Sustained release effects in vivo; enhanced antiangiogenic properties in HUVEC.                   | 17–350                 | Unspecified                                                                                       |
| Varshochian R, et al<sup>200</sup> 2015 | Eye posterior segment neovascularization    | Rabbit mode         | Bevacizumab   | PLGA-albumin nanoparticles        | Double-emulsion solvent evaporation   | Sustained release bevacizumab for about 2 months after intravitreal injection and increased half-life of drug in vivo. | 190                    | Unspecified                                                                                       |
| Lu Y, et al<sup>203</sup> 2014   | Diabetic retinopathy                         | Rabbit model        | Bevacizumab   | Chitosan nanoparticles            | Unspecified                          | Sustained release effects in vivo; inhibition of VEGF expression in vivo.                      | 88.9                   | The preparation of nanoparticle should be optimized to achieve the goal of reducing intravitreal injection and the occurrence of complications in clinical practices. |
Nano-Suspensions
Nano-suspensions, particularly cationic suspensions, are suitable for ocular administration of poorly soluble and poorly absorbed drugs. However, most of the suspending agents for nano-suspensions are surfactants, which may be irritating and toxic to the eyes. Therefore, encapsulating the nano-suspension into a suitable gel matrix or bioadhesive matrix, or even preparing an ophthalmic implant, may produce superior sustained release effects. In addition, the stability of a nano-suspension is insufficient compared with other colloidal particle systems, and storage time is shorter under the same conditions.

Microemulsions/Nanoemulsions
Micro and nanoemulsions also used as ophthalmic preparation carriers, but droplet size, long-term stability, and the toxicity caused by the large number of surfactants and co-surfactants restrict their wide application. Therefore, it is necessary to focus on the irritation caused by nanoemulsions.

Nanomicelles
PLGA nanomicelles have problems, such as relatively low drug loading, unsuitable release rate control, and difficulty in large-scale production, which have also become an important obstacle to their wide application in sustained drug release. In addition, PLGA nanomicelles contact or enter the eye as a foreign body, and their potential toxicity to eye tissues requires further study.

Polymeric and Lipid Nanoparticles
Polymeric and lipid nanoparticles have a strong carrying capacity for fat-soluble substances, but insufficient carrying capacity for water-soluble substances. To achieve an optimal effect in the case of topical nano-formulations, it is highly desirable to engineer bioadhesive/mucoadhesive nano-systems to enhance the reactivity and bioavailability of nano-systems in the ocular cul-de-sac.

Anti-VEGF Agents
The main challenges for an anti-VEGF agent delivery system based on nanotechnology focus on loading molecules that maintain their biological activity after being released from the nanoparticle system, and studying formulation stability, pharmacokinetics, and efficacy in vivo and in vitro models.

Future Prospects
Nanotechnology-based therapeutics have revolutionized the prevention of ocular disorders. Although there is a distinct advantage over commonly used ocular administration routes (intravitreal, topical, systemic, and periocular), all approaches are still limited to pre-clinical studies with several challenges need to be overcome, eg, large-scale manufacturing, and late phase clinical trials to enable scholars to achieve robust findings and evidence. Furthermore, future development of an ideal nanoscale clinical drug delivery vehicle should focus on the heterogeneous manifestations of the disease, such as the etiology and pathogenesis. The effects of particle size, surface charge, and composition and aggregation on the pharmacokinetic and pharmaco-toxic profiles need to be determined.

Using active targeting ligands to modify nano-formulations or incorporating penetration enhancers into composite systems may be an effective method for ocular nano-carrier DDSs to deliver drugs to the posterior segment of the eye, but studies concerning the uptake of targeted nano-carriers in the treatment of posterior-segment ocular diseases are scarce. Studies are needed to fill these gaps and overcome the problems associated with nano-carriers functionalized with multiple ligands of cells and tissues of the posterior eye as vehicles.

Many excellent nano-carrier DDS therapeutics require innovation to treat ocular disorders. For example, myopia also known as short-sightedness or nearsightedness, has become a serious public health problem worldwide. The number of individuals with myopia has reached nearly 2 billion worldwide, which includes 277 million individuals with high myopia. Pharmacological strategies to control myopia include the non-specific anti-muscarinic agent atropine and the M1 receptor-specific antagonist pirenzepine. Atropine is the most widely studied agent for this indication, and once-daily topical low-concentration atropine eye drops effectively control the development of myopia. However, there is little evidence on the ocular bioavailability of low-concentration eye drops. Due to the limited retention time of the drug in the conjunctival sac and low bioavailability, a nano-carrier DDS should be developed to load topical low-concentration atropine. The drug may achieve sustained release and improve the curative effect, which has potential value for the control of myopia.
Conclusion
The penetration and delivery of drugs is particularly difficult under the complex and multiple physiological ocular barriers. Traditional drug preparations, such as eye drops, have a good therapeutic effect for anterior eye diseases, but there are some shortcomings, such as low bioavailability, frequent drug use, poor permeability. Intravitreal injection of drugs overcomes the ocular barrier for posterior eye diseases and achieves a therapeutic effect, but it has a high risk of various complications and adverse reactions which have brought great challenges to the treatment of diseases. Therefore, research and development of new DDSs are needed to better deliver drugs to the eyes and prolong the duration of drugs in the eyes.

Scientists have actively studied a variety of nanocarrier DDSs, such as liposomes, nanoemulsions, nanoparticles, nano-suspensions and nanomicelles, which show excellent delivery potential in vitro and in vivo animal models, and prolong the retention time in the eye, suggesting that nano-carrier DDSs are a good application prospect in ocular drug therapy approaches and have potential value for further clinical development.

Abbreviations
5-FU, fluorouracil; AMD, Age-related macular degeneration; AUC, area under the curve; BAB, blood-aqueous barrier; BRB, blood retinal barrier; CeCl3@mSiO2, prepared cerium (III) chloride (CeCl3)-loaded mesoporous silica; CeO2-NPs, synthesized cerium oxide nanoparticles; CH-MEs, chitosan-coated cationic microemulsions; CNTF, ciliary neurotrophic factor; CVN, choroidal neovascularization; CSa, cyclosporine; CT, Nano-coated tomography; DDSs, drug delivery systems; DED, Dry eye disease; DM, diabetes mellitus; DR, Diabetic retinopathy; DSP, dexamethasone sodium phosphate; DSP-Zn-NP, dexamethasone sodium phosphate using zinc ion bridging; EAU, experimental autoimmune uveoretinitis; ERK1/2, extracellular signal-regulated kinase; HA, hyaluronic acid; IC50, the 50% inhibitory concentration; ICAM-1, intercellular adhesion molecule-1; IGF, insulin-like growth factor-I; IOL, intra ocular lens; IOP, intraocular pressure; K5, Kringle 5; K5-NP, K5-carrying PLGA nanoparticles; LECs, lens epithelial cells; LPD, liposome-protamine-DNA complex; MEs, microemulsions; mPEG-PCL, glycol-block-polycaprolactone; mTOR, mechanistic target of rapamycin; NEs, nemaemulsion; NSAIDs, non-steroidal anti-inflammatory drugs; OPP, osteopontin peptide; PAP2, production of anthocyanin pigment 2; PAP4, production of anthocyanin pigment 4; PCNPs, synthesized cerium oxide nanoparticles (CeO2-NPs) coated with PEG-PLGA; PEG, poly (ethylene glycol); PLGA, poly lactic co-glycolic acid; PRN, “pro re nata”; PVCL-PVA-PEG, polyvinyl caprolactam-polyvinyl alcohol-polyethylene glycol; Rb, Retinoblastoma; RGC, retinal ganglion cell; ROP, Retinopathy of prematurity; ROS, reactive oxygen species; siRNA, small interfering RNA; STZ, streptozotocin; T&E, “treat and extend”; TA, triamcinolone acetonide; TNF-α, tumor necrosis factor-α.

Acknowledgments
The authors would like to acknowledge financial support from the National Natural Science Foundation of China (No. 81300783; 82003882), China Postdoctoral Science Foundation (No. 2019TQ0358; 2019M661162), LiaoNing Revitalization Talents Program (No. XLYC1807082), Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program (grant number RC190146).

Disclosure
The authors declare no conflicts of interest in this work.

References
1. Ensign LM, Cone R, Hanes J. Nanoparticle-based drug delivery to the vagina: a review. J Controlled Release. 2014;190:500–514. doi:10.1016/j.jconrel.2014.04.033
2. Adelli GR, Bhagav P, Taskar P, et al. Development of a Δ9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability. Invest Ophthalmol Vis Sci. 2017;58:2167–2179. doi:10.1167/iovs.16-20757
3. Weinreb RN, Robinson MR, Dibas M, Stanner WD. Matrix metalloproteinases and glaucoma treatment. J Ocul Pharmacol Ther. 2020;36:208–228. doi:10.1089/jop.2019.0146
4. DeSantis L. Preclinical Overview of Brinzolamide. Surv Ophthalmol. 2000;44:S19–S29. doi:10.1016/S0039-6257(99)00108-3
5. Mehta M, Deeksha SN, Vyas M, et al. Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases. Chem Biol Interact. 2019;304:10–19. doi:10.1016/j.cbi.2019.02.021
6. Drescher S, van Hoogevest P. The phospholipid research center: enhanced solubility, stability, and bioavailability. Molecules. 2020;1:25.
7. Zheng B, McClements DJ. Formulation of more efficacious curcumin delivery systems using colloid science: enhanced solubility, stability, and bioavailability. Molecules. 2020;1:25.
8. Yavuz B, Pehlivan SB, Unli N. Dendrimeric systems and their applications in ocular drug delivery. ScientificWorldJournal. 2013;2013:732340. doi:10.1155/2013/732340
9. Bozzuto G, Molinari A. Liposomes as nanomedical devices. *Int J Nanomedicine*. 2015;9:755–999. doi:10.2147/IJN.S68861
10. Baujat B, Krastinova D, Bach CA, Coquille F, Chabolle F. Orbital morphology in exophthalmos and exorbitism. *Plast Reconstr Surg*. 2006;117:542. doi:10.1097/01.PR.000020773.00268.56
11. Gupta A, Kafetzis KN, Tagalakis AD, Yu-Wai-Man C. RNA therapeutics in ophthalmology - translation to clinical trials. *Exp Eye Res*. 2021;205:108482. doi:10.1016/j.exer.2021.108482
12. Fischer N, Narayanan R, Loewenstein A, Kuppermann BD. Drug Delivery to the posterior segment of the eye. *Eur J Ophthalmol*. 2010;21:20–26. doi:10.5301/EJO.2010.6051
13. Braakhuis AJ, Donaldson CI, Lim JC, Donaldson PJ. Nutritional Strategies to Prevent Lens Cataract: current Status and Future Strategies. *Nutrients*. 2019;1:1:11
14. Xu X, Al-Ghaibish M, Rahman Z, et al. Formulation and processing factors influencing product quality and in vitro performance of ophthalmic ointments. *Int J Pharm*. 2015;493:412–425. doi:10.1016/j.ijpharm.2015.07.066
15. Shi XH, Wei WB. [Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia]. *Zhonghua Yan Ke Za Zhi*. 2019;53:791–795. Chinese.
16. Stewart MW. Extended duration vascular endothelial growth factor inhibitor in the eye: failures, successes, and future possibilities. *Pharmaceutics*. 2018;10.
17. Kiser PD, Zhang J, Badiee M, et al. Rational tuning of visual cycle modulator pharmacodynamics. *J Pharmacol Exp Ther*. 2017;362:131–145. doi:10.1124/jpet.117.240721
18. Kesav NP, Young CEC, Ertel MK, Seibold LK, Kahook MY. Sustained-release drug delivery systems for the treatment of glaucoma. *Int J Ophthalmol*. 2021;14:148–159. doi:10.18240/ijo.2021.01.21
19. Sharaf MG, Cetinel S, Heckler L, Damki J, Unsworth L, Montemagnino C. Nanotechnology-Based Approaches for ophthalmology applications: therapeutic and diagnostic strategies. *Asia Pac J Ophthalmol*. 2014;3:172–180. doi:10.1097/APO.0000000000000059
20. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. *Molecules*. 2020;25.
21. Vaishya RD, Khurana V, Patel S, Mitra AK. Controlled ocular drug delivery with nanomicelles. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2014;6:422–437. doi:10.1002/wnn.1272
22. Honda M, Narayanan R, Loewenstein A, Kuppermann BD. Drug Delivery to the posterior segment of the eye. *Eur J Ophthalmol*. 2010;21:20–26. doi:10.5301/EJO.2010.6051
23. Sasawaka T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda M, Asai T, Oku N, Araki Y, Tanaka M, Ebihara N. Metabolism of graphene quantum dots. *Nanomedicine*. 2019;14:1889–1909. doi:10.2217/nnm-2019-0040
24. Wang Y, Rajala A, Rajala RVS. Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases. *Adv Exp Med Biol*. 2018;1074:117–123.
25. Wang X, Wang S, Zhang Y. Advance of the application of nano-controlled release system in ophthalmic drug delivery. *Drug Deliv*. 2016;23:2897–2901. doi:10.3109/10717544.2015.116025
26. Xu J, Zheng S, Hu X, et al. Advances in the Research of Bioinks Based on Natural Collagen, Polysaccharide and Their Derivatives for Skin 3D Bioprinting. *Polymers*. 2020;12(6):1237. doi:10.3390/polym12061237
27. Zhang et al.
47. Xu J, Zheng S, Hu X, et al. Advances in the research of bioinks based on natural collagen, polysaccharide and their derivatives for skin 3d bioprinting. Polymers. 2020;12.
48. Varshochian R, Riazi-Esfahani M, Jeddii-Tehrani M, et al. Albuminun PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A. 2015;103:3148–3156. doi:10.1002/jbm.a.35446
49. Mahaling B, Srinivasarao DA, Raghu G, Kasam RK, Bhanuprakash Reddy G, Katti DS. A non-invasive nanoscale-mediated delivery of triamcinolone acetonide ameliorates diabetic retinopathy in rats. Nanoscale. 2018;10:16485–16498. doi:10.1039/C8NR00058A
50. Wang B, Tang Y, Oh Y, et al. Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization. Nanomed. 2019;17:119–123. doi:10.1016/j.nano.2019.01.001
51. Luschmann C, Herrmann W, Strauss O, Luschmann K, Goepferich A. Ocular delivery systems for poorly soluble drugs: an in-vivo evaluation. Int J Pharm. 2013;455:331–337. doi:10.1016/j.ijpharm.2013.07.002
52. Ali HSM, York P, Ali AM, Blagden N. Hydrocorrosion nano-suspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling. J Control Release. 2011;149:175–181. doi:10.1016/j.jconrel.2010.07.007
53. Abrego G, Alvarado HL, Egea MA, Gonzalez-Mira E, Calpena AC, Garcia ML. Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of panopronfen. J Pharm Sci. 2014;103:3153–3164. doi:10.1002/jps.24101
54. Giménez-Millán E, Quintans-Carballo M, Otero-Espinar FJ. Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug suspensions. Int J Pharm. 2017;525:226–236. doi:10.1016/j.ijpharm.2017.03.082
55. Mudgil M, Pawar PK. Preparation and in vitro/ex vivo evaluation of moxifloxacin-loaded plga nanosuspensions for ophthalmic application. Sci Pharm. 2013;81:591–606. doi:10.3797/scipharm.1204-16
56. Kamaleddin MA. Nano-ophthalmology: applications and considerations. Nanomedicine. 2017;13:1459–1472. doi:10.1016/j.nano.2017.02.007
57. Li X, Zhang Z, Li J, Sun S, Weng Y, Chen H. Diclofenac/imbeiglucorred polymer micelles for ocular applications. Nanoscale. 2012;4:4667–4673. doi:10.1039/c2nr20392f
58. Grimaudo MA, Pescina S, Padula C, et al. Poloxamer 407/TPGS Mixed micelles as promising carriers for cyclosporine ocular delivery. Mol Pharm. 2018;15:571–584. doi:10.1021/acs.molpharmaceut.7b00939
59. Wu W, He Z, Zhang Z, Yu X, Song Z, Li X. Intravitreal injection of rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model. Int J Pharm. 2016;513:238–246. doi:10.1016/j.ijpharm.2016.09.013
60. Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Trans Vis Sci Technol. 2015;4:1. doi:10.1167/tvst.4.3.1
61. Stefañek A, Leczycka-Wilk K, Czarnocka-Sniadala S, et al. Fluorouracilantactants for medical nanoemulsions, their surface-active and biological properties. Colloids Surf B Biointerfaces. 2021;200:111603. doi:10.1016/j.colsurfb.2021.111603
62. Speglova M, Cuchorova M, Cierna M, Ponist S, Bauerova K. Microemulsions as solubilizers and penetration enhancers for minoxidil release from gels. Gels. 2021;7.
63. Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NADSAIs: safety on drug delivery. Nanomed. 2009;5:394–401. doi:10.1016/j.nano.2009.02.003
64. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13:144–151. doi:10.1016/j.drudis.2007.10.021
65. Damiani G, Eggenhöffner R, Pigatto PDM, Bragazzi NL. Nanotechnology meets atopic dermatitis: current solutions, challenges and future prospects. Insights and implications from a systematic review of the literature. Bioact Mater. 2019;4:380–386. doi:10.1016/j.bioactmat.2019.11.003
66. Kalam MA, Alshamsan AJ, Aljuffali IA, Mishra AK, Sultana Y. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Deliv. 2016;23:896–907. doi:10.3109/10717544.2014.920432
67. Kesavan K, Kant S, Singh PN, Pandit JK. Mucocadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Curr Eye Res. 2013;38:342–352. doi:10.3109/02713683.2012.745879
68. Vigani B, Rossi S, Sandri G, Bonferroni MC, Caramella CM, Ferrari F. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. Pharmaceutics. 2020;12.
69. Al-Kinani AA, Zidan G, Elsaind N, Seyfoddin A, Alani AWG, Alany RG. Ophthalmic gels: past, present and future. Adv Drug Deliv Rev. 2018;126:113–126. doi:10.1016/j.addr.2017.12.017
70. Lin S, Ge C, Wang D, et al. Overcoming the anatomical and physiological barriers in topical eye surface medication using a peptide-decorated polymeric micelle. ACS Appl Mater Interfaces. 2019;11:39603–39612. doi:10.1021/acsami.9b13851
71. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Development of dorzolamide hydrochloride in situ gel nanoeumulsion for ocular delivery. Drug Dev Ind Pharm. 2010;36:1330–1339. doi:10.3109/03639041003801885
72. Göttel B. Electrospun nanofibers - A promising solid-in-situ gelling alternative for ocular drug delivery. Eur J Pharm Biopharm. 2020;146:125–132. doi:10.1016/j.ejpb.2019.11.012
73. Li H, Xin HL, Muller DA, Estoff LA. Visualizing the 3D internal structure of calcite single crystals grown in aragonite hydrogels. Science. 2009;326:1244–1247. doi:10.1126/science.1178583
74. Göttel B, de Souza ESJM. Electrospun nanofibers - A promising solid-in-situ gelling alternative for ocular drug delivery. Eur J Pharm Biopharm. 2020;146:125–132.
75. Ryder EC, Benson S. Conunctivitis. Treasure Island (FL): StatPearls Publishing; 2020.
76. Yasin MN, Hussain S, Malik F, et al. Preparation and characterization of chlorampenicol niosomes and comparison with chloramphenicol eye drops (0.5% w/v) in experimental conjunctivitis in albino rabbits. Pak J Pharm Sci. 2012;25:117–121.
77. Svekavi CL, Galani IE, Pararas MV, Giannopoulou KP, Tsakris A. Treatment of viral conjunctivitis with antiviral drugs. Drugs. 2011;71:331–347. doi:10.2165/11585330-000000000000-0000
78. Bourcier T, Sauer A, Dory A, Denis J, Sabou M. Fungal keratitis. J Fr Ophtalmol. 2017;40:e307–e13. doi:10.1016/j.jfo.2017.08.001
79. Fan P-S, Sun M-J, Qin D, Yuan C-S, Chen X-G, Liu Y. Development of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. J Mater Chem B. 2021;9(7):1729–1744. doi:10.1039/D0TB02590A
80. Chlonker YS, Prasad YD, Chandasa H, et al. Amphotericin-B entrapped lecitin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol. 2015;72:1451–1458. doi:10.1016/j.jbiomac.2014.10.014
118. Li M, Xu Z, Zang L, et al. Targeted Noninvasive treatment of chorioidal neovascularization by hybrid cell-membrane-cloaked biomimetic nanoparticles. ACS Nano. 2021;15:9808–9819. doi:10.1021/acsnano.1c06680

119. Jin J, Zhou KK, Park K, et al. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenesis inhibitor. Invest Ophthalmol Vis Sci. 2011;52:6230–6237. doi:10.1167/iovs.10-6229

120. Brown AC, Nwanyanwu K. Retinopathy of Prematurity: Treasure Island (FL): StatPearls Publishing; 2020.

121. Kim JH, Kim MH, Jo DH, YuYS, Lee TG, Kim JH. The inhibition of retinal neovascularization by gold nanoparticles via suppression of VEGFR-2 activation. Biomaterials. 2011;32:1865–1871.

122. Committee for the National Registry of R. The National Registry of Retinoblastoma in Japan (1983–2014). Jpn J Ophthalmol. 2018;62:409–423. doi:10.1016/s0022-9915(17)30097-2

123. Qu W, Meng B, Yu Y, Wang S. Folic acid-conjugated mesoporous silica nanoparticles for enhanced therapeutic efficacy of topotecan in retina cancers. Int J Nanomedicine. 2018;13:4379–4389. doi:10.2147/IJN.S142668

124. Delrish E, Jabbarvand M, Ghassemi F, et al. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma. Exp Eye Res. 2021;204:108423. doi:10.1016/j.exer.2020.108423

125. You Y, Gupta VK, Li JC, Klistorner A, Graham SL. Anti-inflammatory activity.

126. Committee for the National Registry of R. The National Registry of Retinoblastoma in Japan (1983–2014). Jpn J Ophthalmol. 2018;62:409–423. doi:10.1016/s0022-9915(17)30097-2

127. Yao A, van Wijngaarden P. Metabolic pathways in context: evidences of improved biopharmaceutical performance and stability study. Eur J Pharm Biopharm. 2020;120:107–110. doi:10.1016/j.ejpb.2018.06.014

128. Li N, Wang F, Zang Q, et al. Rapamycin mediates mTOR signaling in reactive astocytes and reduces retinal ganglion cell loss. Exp Eye Res. 2018;176:10–19. doi:10.1016/j.exer.2018.06.014

129. Chrisen AZ, Eliasen R, Oswald J, et al. Multifarious biologic loadings liposomes that stimulate the mammalian target of rapamycin signaling pathway show retina neuroprotection after retina damage. ACS Nano. 2018;12:7497–7508. doi:10.1021/acsnano.8b00596

130. Burkholder BM, Jabs DA. Uveitis for the non-ophthalmologist. BMJ. 2021;372:m4979. doi:10.1136/bmj.m4979

131. Nirbhavane P, Sharma G, Singh B, et al. Triamcinolone acetonide preparation and evaluation of cubosomes/cubosomal gels for delivery of uveitis. Eur J Pharm Sci. 2018;103:841–848. doi:10.1016/j.ejps.2018.05.011

132. Mehra N, Aqil M, Sultana Y. A grafted copolymer-based nanoparticles as a delivery system for improving antiangiogenic therapy in neovascular ocular pathologies. Mater Sci Eng C Mater Biol Appl. 2020;105:105735. doi:10.1016/j.msec.2020.105735

133. Kim H, Sung J, Chang Y, Alfeche A, Leal C. Microfluidics for macular degeneration. Adv Ther. 2019;36:611–619. doi:10.1007/s12325-017-0484-0

134. Enriquex AB, Avery RL, Baumal CR. Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity. Asia Pac J Ophthalmol. 2020;9:358–368. doi:10.1097/APO.0000000000000302

135. Formica ML, Legesay S, Bejaud J, et al. Novel hybrid lipid nanoparticles loaded with a therapeutic monoclonal antibody - Bevacizumab - and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies. Mater Sci Eng C Mater Biol Appl. 2021;119:111398. doi:10.1016/j.msec.2020.111398

142. Barar J, Aghanejad A, Fathi M, Omidi Y. Advanced drug delivery strategies based on nanotechnology. Expert Opin Drug Deliv. 2016;13:8401–8416. doi:10.1016/j.acsnano.9604050

143. Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R. Clinical pharmacology of intravitreal anti-VEGF drugs. Eye. 2018;32:1010–1020. doi:10.1038/s41433-018-0021-7

144. Androudi S, Dastiridou A, Pharmacakis N, et al. Guidelines for the management of wet age-related macular degeneration: recommendations from a panel of Greek experts. Adv Ther. 2016;33:715–726. doi:10.1007/s12325-016-0332-7

145. Ng DSC, Fung NSK, Yip FLT, Lai TYY. Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther. 2020;20:1385–1393. doi:10.1080/14712598.2020.1830969

146. Villegas VM, Schwartz SG. Current and future pharmacologic therapies for diabetic retinopathy. Curr Pharm Des. 2018;24:4903–4910. doi:10.2174/1381612825666190130140717

147. propane, dexamethasone (A) and its enantiomer, dexketoprofen (S(+)-KP).

148. Zarbin MA. Anti-VEGF agents and the risk of arteriothrombotic events. Clin Exp Pharmacol Physiol. 2012;39:63–67. doi:10.1111/j.1440-1681.2011.05962.x

149. Sun XJ, Zhang XY, et al. Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy. Int J Nanomedicine. 2019;14:1489–1501. doi:10.2147/IJN.S195504

150. Lquis de Redin I, Boiero C, Recalde S, et al. In vivo effect of bevacizumab-loaded albumin nanoparticles in the treatment of corneal neovascularization. Exp Eye Res. 2019;185:107697. doi:10.1016/j.exer.2019.107697

151. Mennillo E, Krokje A, Pretti C, Meucci V, Arukwe A. Preparation and evaluation of cubosomes/cubosomal gels for ocular delivery of beclomethasone dipropionate for management of uveitis. Pharm Res. 2020;37:198. doi:10.1007/s11095-020-02857-1

152. Ryan EH. Current treatment strategies for symptomatic vitreous opacities. Curr Opin Ophthalmol. 2021;32:198–202. doi:10.1097/ICO.0000000000000752

153. Sauvage F, Fraire JC, Renaut K, et al. Photoablation of Human vitreous opacities by light-induced vapor nanobubbles. ACS Nano. 2019;13:8401–8416. doi:10.1021/acsnano.9b04050

154. Baird PN, Saw S-M, Lana C, et al. Myopia. Nat Rev Dis Primers. 2020;9.
155. Pineles SL, Kraker RT, VanderVeen DK, et al. Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124:1857–1866. doi:10.1016/j.ophtha.2017.05.032

156. Walline JJ. Myopia Control: a Review. Eye Contact Lenses. 2016;42:3–8. doi:10.1097/ICL.0000000000000207

157. Walline JJ, Lindsey KB, Vedula SS, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2020;CD004916.

158. Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123:697–708. doi:10.1016/j.ophtha.2015.11.010

159. Sanchez-Lopez E, Estereulas G, Ortiz A, et al. Dibuxiprofen Biodegradable Nanoparticles: one Step Closer towards a Better Ocular Interaction Study. Nanomaterials. 2020;10.

160. Gai X, Cheng L, Li T, et al. In vitro and in vivo studies on a novel bioadhesive colloidal system: cationic liposomes of ibuprofen. AAPS PharmSciTech. 2018;19:700–709. doi:10.1208/s12249-017-0872-4

161. Yu F, Zheng M, Zhang YA, Han Z. A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease. Nanomedicine. 2017;164.

162. Schnichels S, Hurst J, de Vries JW, et al. Self-assembled DNA nanoparticles. Int J Nanomedicine. 2020;15:3264–3275. doi:10.2147/IJN.S329831

163. Sanchez-Lopez E, Estereulas G, Ortiz A, et al. Dibuxiprofen Biodegradable Nanoparticles: one Step Closer towards a Better Ocular Interaction Study. Nanomaterials. 2020;CD004916.

164. Di Tommaso C, Torriglia A, Furrer P, Behar-Cohen F, Gurny R, Yu F, Zheng M, Zhang AY, Han Z. A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease. Nanomedicine. 2018;13:7251–7273. doi:10.2147/INJ.S173198

165. Walline JJ, Lindsley KB, Vedula SS, et al. Interventions to slow progression of myopia in children: a network meta-analysis. Ophthalmology. 2016;123:697–708. doi:10.1016/j.ophtha.2015.11.010

166. Sanchez-Lopez E, Estereulas G, Ortiz A, et al. Dibuxiprofen Biodegradable Nanoparticles: one Step Closer towards a Better Ocular Interaction Study. Nanomaterials. 2020;10.

167. Gai X, Cheng L, Li T, et al. In vitro and in vivo studies on a novel bioadhesive colloidal system: cationic liposomes of ibuprofen. AAPS PharmSciTech. 2018;19:700–709. doi:10.1208/s12249-017-0872-4

168. Rathod LV, Kapadia R, Sawant KK. A novel nanoparticles impregnated ocular insert for enhanced bioavailability to posterior segment of eye: in vitro, in vivo and stability studies. Mater Sci Eng C Mat Biol Appl. 2017;71:529–540. doi:10.1016/j.msec.2016.10.017

169. Ikuta Y, Aoyagi S, Tanaka Y, et al. Creation of nano eye drops and effective drug delivery to the interior of the eye. Sci Rep. 2017;7:44229. doi:10.1038/srep44229

170. Kouchak M, Bahmandar R, Bavarsad N, Farrahi F. Ocular dorzolamide nanoliposomes for prolonged IOP reduction: in vitro and in vivo evaluation in rabbits. Iran J Pharm Res. 2016;15:205–212.

171. Yu S, Wang QM, Wang X, et al. Liposome incorporated ion sensitive in situ gels for ophthalmic delivery of timolol maleate. Int J Pharm. 2015;480:128–136. doi:10.1016/j.ijpharm.2015.01.032

172. Singh J, Chhabra G, Pathak K. Development of acetazolamide-loaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro, ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm. 2014;40:1223–1232. doi:10.3109/03639045.2013.814061

173. Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014;467:34–41. doi:10.1016/j.ijpharm.2014.03.048

174. Mishra V, Jain NK. Acetazolamide encapsulated dendritic nano-architectures for effective glaucoma management in rabbits. Int J Pharm. 2014;461:380–390. doi:10.1016/j.ijpharm.2013.11.043

175. Jung HJ, Abou-Jaoude M, Carbia BE, Plummer C, Chauhan A. Glaucoma therapy by extended release of timolol from nanoparticle loaded silicone-hydrogel contact lenses. J Control Release. 2013;165:82–89. doi:10.1016/j.jconrel.2012.10.010

176. Wu W, Li J, Wu L, et al. Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: in vitro and in vivo evaluation. AAPS PharmSciTech. 2013;14:1063–1071. doi:10.1208/s12249-013-9997-2

177. Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatarman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine. 2012;7:123–131.

178. Tang M, Ji X, Xu H, et al. Photostable and biocompatible fluoroscent silicon nanoparticles-based theranostic probes for simultaneous imaging and treatment of ocular neovascularization. Anal Chem. 2018;90:8188–8195. doi:10.1021/acs.analchem.8b01580

179. Hsu VA, Luo J, Zhu J, et al. Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye. J Control Release. 2015;200:71–77. doi:10.1016/j.jconrel.2015.01.001

180. Luo L, Zhang X, Hirano Y, et al. Targeted intraretro nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013;7:3264–3275. doi:10.1021/nn305958y

181. Iwase T, Fu J, Yoshida T, et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release. 2013;172:625–633. doi:10.1016/j.jconrel.2013.10.008

182. Kyosseva SV, Chen L, Seal S, McGinnis JF. Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice. Exp Eye Res. 2013;116:63–74. doi:10.1016/j.exer.2013.08.003

183. Yandrapu SK, Upadhyay AK, Petras JH, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013;10:4676–4686. doi:10.1021/mp400487f

184. Jo DH, Kim JH, Yu YS, Lee TG, Kim JH. Antiangiogenic effect of silicate nanoparticle on retinal neovascularization induced by vascular endothelial growth factor. Nanomedicine. 2012;8:78–89. doi:10.1016/j.nano.2011.09.003

185. Iezzi R, Guru BR, Glybina IV, Mishra MK, Kennedy A, Kannan RM. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials. 2012;33:979–988. doi:10.1016/j.biomaterials.2011.10.010

186. Liu HA, Liu YL, Ma ZZ, Wang JC, Zhang Q. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model. Invest Ophthalmol Vis Sci. 2011;52:4789–4794. doi:10.1167/iovs.10-5891

187. Zhang C, Wang YS, Wu H, et al. Inhibitory efficacy of hypoxia-inducible factor alpfa short hairpin RNA plasmid DNA-loaded poly (D-Lactide-co-glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model. Gene Ther. 2010;17:338–351. doi:10.1038/gt.2009.151

188. Garg V, Nirmal J, Riadi Y, Kesharwani P, Kohli K, Jain GK. Amelioration of endotoxin-induced uveitis in rabbit by topical administration of tacrolimus propylene oxide-nano-vesicles. J Pharm Sci. 2021;110:871–875. doi:10.1016/j.xphs.2020.10.060
189. Coburn PS, Miller FC, LaGrow AL, et al. Disarming Pore-forming toxins with biomimetic nanosponges in intraocular infections. mSphere. 2019;4.
190. Chennamaneni SR, Mamalis C, Archer B, Oakey Z, Ambati BK. Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation. J Control Release. 2013;167:53–59. doi:10.1016/j.jconrel.2013.01.007
191. Elbiały NS, Abdol-Azim BM, Shafaa MW, El Shazly LH, El Shazly AH, Khalil WA. Enhancement of the ocular therapeutic effect of prednisolone acetate by liposomal entrapment. J Biomed Nanotechnology. 2013;9:2105–2116. doi:10.1166/jbn.2013.1711
192. Liu J, Zhang X, Li G, et al. Anti-angiogenic activity of bevacizumab-bearing dexamethasone-loaded plga nanoparticles for potential intravitreal applications. Int J Nanomedicine. 2019;14:8819–8834. doi:10.2147/IJN.S217038
193. Savin CL, Popa M, Delaite C, Costuleanu M, Costin D, Peptu CA. Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab. Mater Sci Eng C Mater Biol Appl. 2019;98:843–860. doi:10.1016/j.msec.2019.01.036
194. Urlu N, Asik MD, Cakmak HB, Tuncer S, Turk M. Transscleral Delivery of Bevacizumab-Loaded Chitosan Nanoparticles. J Biomed Nanotechnology. 2019;15:830–838. doi:10.1166/jbn.2019.192716
195. Llibot JM, Luis de Redin I, Agüeros M. In vitro characterization of new stabilizing albumin nanoparticles as a potential topical drug delivery system in the treatment of corneal neovascularization (CNV). J Drug Deliv Sci Technol. 2019;52:379–385. doi:10.1016/j.jddst.2019.04.042
196. Zhang XP, Sun JG, Yao J, et al. Effect of nanoencapsulation using poly(lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. Biomed Pharmacother. 2018;107:1056–1063. doi:10.1016/j.biopharm.2018.08.092
197. Yan J, Peng X, Cai Y, Cong W. Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy. J Photochem Photobiol B. 2018;183:133–136. doi:10.1016/j.jphotobiol.2018.04.033
198. Karumanchi DK, Skrypai Y, Thomas A, Gaillard ER. Rational design of liposomes for sustained release drug delivery of bevacizumab to treat ocular angiogenesis. J Drug Deliv Sci Technol. 2018;47:275–282. doi:10.1016/j.jddst.2018.07.003
199. Mu H, Wang Y, Chu Y, et al. Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization. Drug Deliv. 2018;25:1372–1383. doi:10.1080/10717544.2018.1474967
200. Pandit J, Sultana Y, Aqil M. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol. 2017;45:1397–1407. doi:10.1080/10717544.2016.1243545
201. Sousa F, Cruz A, Fonte P, Pinto IM, Neves-Petersen MT, Sarmento B. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep. 2017;7:3736. doi:10.1038/s41598-017-03959-4
202. Elsaid N, Jackson TL, Elsaid Z, Alqatham A, Somavarapu S. PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab. Mol Pharm. 2016;13:2923–2940. doi:10.1021/acs.molpharmaceut.6b00335
203. Lu Y, Zhou N, Huang X, et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol. 2014;7:1–7.